Genopole®

Enterprises

Enterprises

AGRICULTURE/ENVIRONMENT

CONSULTANCY

DIAGNOSTICS

MEDICAL DEVICES

COMPUTING AND IT

SCIENTIFIC INSTRUMENTATION

R&D SERVICES

THERAPEUTICS

CONTACT

Eric Lameignère
Director
eric.lameignere@genopole.fr

Acriter

FIELD OF ACTIVITY

\ Support for corporate organizational development in life sciences.
\ Support for research-driven project management in innovative drug discovery and development.

KEYWORDS

\ Consultancy \ Pharma and biotech R&D project management \ Project management training.

Director \Frédéric DOC

Contact details \ Immeuble Le Magellan
7, rue Montespan - F-91024 EVRY Cedex
Tel \ +33 1 69 47 60 45 Fax \ +33 1 69 47 60 70
E-mail \ info@acriter-consulting.com
Web site \ www.acriter-consulting.com
Date of founding \ 21st June 2004

DESCRIPTION

Background

Acriter's 3 co-founders have in-depth expertise in the main areas of pharmaceutical research (pharmacology, medicinal chemistry and pharmaceutical science). They have also acknowledged experience in the management of large-scale projects.

Description of the products/services/technology

Consulting activity

- Initiation and development of scientific collaborations
- New business start-up project development
- Planning and piloting research-driven project activities which aim at reducing the late-stage attrition rate (mainly focused on chemistry, pharmacology, formulation, pharmacokinetics and metabolism)
- Continuous process improvement initiatives for supporting research activity performance and productivity

Training sessions (can be adapted according to common constraints).

- The drug discovery process: research-stage actions for tackling late attrition.
- Research-driven project management.
- Research-dedicated information systems: IT tool design and project management development.

Customer references/collaborations/highlights

Training sessions for biotech companies at the LEEM (the French pharmaceutical industry association). Acriter is contractually obliged to withhold the names of customers having used its know-how to optimize their R&D project management.

Collaborations sought

Pharmaceutical and biotech companies (training on R&D process improvement and outsourced project management).

→ **ANNUAL TURNOVER:** €200 K → **3 SALARIED STAFF**

→ **STRENGTHS:** responsiveness, adaptability, expertise in the management of pharmaceutical development projects, strong commitment from its staff.
→ **INNOVATION ASSETS:** custom-designed services.

Aelred

President \ Pierre MALVOISIN

Contact details \ Pépinière Genopole® Enterprises
4, rue Pierre Fontaine - F-91058 EVRY Cedex
Tel \ +33 1 60 87 89 00
E-mail \ malvoisin@aelred.fr
Web site \ www.aelred.fr
Date of founding \ 02/2009

FIELD OF ACTIVITY

\ Custom gene mutation services for the generation of new alleles in any plant species.
\ Development and supply of ingredients extracted from improved varieties (medicinal plants, in particular).

KEYWORDS

\ Tilling® \ Plant biotechnology \ Green chemistry.

DESCRIPTION

Aelred Greenscience offers its services to seed companies and public- or private-sector research laboratories wishing to obtain new alleles for a specific gene or to use the TILLING® technique to confirm the function of a previously uncharacterized gene.

Starting from a collection of mutants (induced mutation), TILLING® enables the screening and characterization of plants mutated in a given gene (the candidate gene) in a relatively short time (one to two years, for an annual plant).

Aelred Greenscience works in close collaboration with the INRA-URGV unit in Evry that developed and perfected this method and has licensed an INRA/Genoplante-Valor patent. Aelred Greenscience is also using TILLING® techniques to improve medicinal plants. The objective is to commercialize the safer, health-promoting ingredients extracted from these plants.

Tilling® is a registered trademark owned by Arcadia Biosciences

→ **ANNUAL TURNOVER: €200,000 (FORECAST FOR 2009)** → **3 SALARIED STAFF**

→ **STRENGTHS:** in-depth knowledge of an innovative plant genomics technology and close collaboration with its originator (INRA-URGV).
→ **INNOVATION ASSETS:** IP/patent protection possible for a mutated gene.

AISA Therapeutics

CEO \ Patrizia D'ALESSIO

Contact details \ Pépinière Genopole® Enterprises
4, rue Pierre Fontaine - F-91058 EVRY Cedex
Tel \ +33 1 45 59 51 46 / +33 6 87 47 80 32
E-mail \ endocell@wanadoo.fr
Date of founding \ 19th Oct. 2005

FIELD OF ACTIVITY

\ AISA Therapeutics develops inflammation modulators. Applications concern (i) therapeutics for inflammatory and auto-immune diseases and (ii) anti-stress and anti-ageing nutraceuticals.

KEYWORDS

\ Anti-inflammatory \ Anti-ageing \ Anti-stress \ Vascular endothelium \ Nutraceuticals \ Plant compounds.

ENTERPRISES

DESCRIPTION

Background

AISA Therapeutics was spun out of a fundamental research program on novel anti-inflammatories at the Descartes University of Paris/Necker Children's Hospital. Since moving to the University of Paris 11 in 2002, AISA Therapeutics has identified and patented 4 plant molecules by using its *in vitro* and *in vivo* screening platforms. In 2007, one of these molecules (AISA 5203-L) gave rise (after preclinical evaluation of oral or topic administration) to two new patents covering tissue repair and the treatment of stress in the skin and the colon.

Description of the products/services/technology

The company is developing its hit AISA 5203-L (D-limonene) and has filed 3 patents. Preclinical studies have revealed that AISA 5203-L has anti-inflammatory effects on the skin and the digestive system, as well as anti-stress and anti-ageing properties. D-limonene targets the adherence molecules in the vascular endothelium via a rhoA-dependent mechanism.

Customer references/collaborations/highlights

AISA Therapeutics is a partner in the European Union FP7 RISTOMED consortium, which aims at preventing ageing-related diseases by monitoring and managing healthy food and nutraceutical intakes in the elderly. The project is seeking to measure the impact of AISA 5203-L in an elderly population (65 to 85 years of age) and notably determine the compound's ability to lower circulating levels of the inflammatory markers that underlie several inflammatory and degenerative diseases in the elderly.

Collaborations sought

AISA Therapeutics is focusing on the development and commercialization (in 2009) of an anti-stress nutraceutical and a cosmetic product designed to keep the skin young.
Three licensing agreements are now being discussed.

→ 3 PATENTS → 2 SALARIED STAFF

→ **STRENGTHS:** a compound that can be exploited in the nutraceutical and pharmaceutical sectors.
→ **INNOVATION ASSETS:** a non-toxic anti-inflammatory compound which is a candidate for long-term treatments.



Algentech SAS

President \ Alexander SOROKIN
CEO \ Isabelle MALCUIT

Contact details \ **Siège social :** Pépinière Genopole®
Entreprises, CAMPUS 1 - 4, rue Pierre Fontaine
F-91058 Evry Cedex
Laboratory : Centre INRA de Versailles, Bat.4, RD10
Route de St Cyr, 78026 Versailles cedex
Tel \ +33 6 88 26 57 04 \+ 33 6 88 26 50 61
E-mail \ asorokin@algentech.com \ imalcuit@algentech.com
Date of founding \ 18th March 2009

FIELD OF ACTIVITY

\ Development of innovative technologies for gene targeting and whole-genome transformation.

KEYWORDS

\ Gene targeting \ Genomics \ Plant biotechnology.

ENTERPRISES

DESCRIPTION

Background

Algentech SAS is using the technology developed over the last 4 years by Algentech Ltd, based in the United Kingdom.

Description of the products/services/technology

Our innovative technologies enable rapid identification and precise targeting of plant genes associated with important agronomic traits, such as yield, disease resistance and abiotic stress resistance. This approach can considerably accelerate selection programs.

Customer references/collaborations/highlights

The company has achieved proof of concept by using target gene modification to induce herbicide resistance in tobacco.

Collaborations sought

Algentech is targeting major plant biotech companies, seed companies and international research organizations.

Arterial Remodeling Technologies (A.R.T.)

FIELD OF ACTIVITY

\ Arterial Remodeling Technologies ("ART") is developing bioresorbable peripheral and coronary artery stents that promote the natural post-angioplasty remodeling of an injured artery. In the mid- to long term, the company is seeking to diversify into the peripheral stent market. The company will remain flexible enough to produce custom stents according to the customer's blueprints.

KEYWORDS

\ Stent \ Biocompatible \ Bioresorbable \ Polymer \ Cardiovascular system.

President \ Machiel VAN DER LEEST

Contact details \ 3, rue de Verdun - Bât G
F-78590 Noisy le Roi
Tel \ +33 1 61 06 19 92
E-mail \ contact@art-stent.com
Web site \ www.art-stent.com
Date of founding \ 21st Nov. 2001

DESCRIPTION

Background

The ART technology is based on IP generated at René Descartes University of Paris V (Professor Antoine Lafont), the Cleveland Clinic Foundation and CNRS Montpellier (Professor Michel Vert).

Description of the products/services/technology

ART is developing a new generation of bioresorbable stents for the treatment of coronary disease.
In addition to having optimal mechanical properties, this stent dismantles itself gradually and degrades fully over time. This helps the artery to remodel itself and heal naturally by recovering its initial luminal profile. The goal is to replace permanently indwelling stents with bioresorbable, transient devices.

The polylactide stent has several advantages: it is non-inflammatory, biocompatible, hemocompatible and mechanically resilient.

Furthermore, ART's stents are (i) compatible with MRI, (ii) visible during angioplasty and (iii) do not require surgeons to change their surgical techniques and habits.

Customer references/collaborations/highlights

University of Montpellier 1, CNRS, University René Descartes Paris V.

→ 1 GRANTED PATENT + 9 PATENT APPLICATIONS → 6 SALARIED STAFF

Assistmov

Project leader \ Mourad BOUZIT

Contact details \ Pépinière Genopole® Enterprises
4, rue Pierre Fontaine - F-91058 EVRY Cedex
Tel \ +33 1 60 87 89 00
E-mail \ mbouzit@gmail.com
Date of founding \ 2009

FIELD OF ACTIVITY

\ Assistmov designs, produces and sells mechatronic solutions (technical aids and man-machine interfaces) for rehabilitation, increased mobility and handicap relief.

KEYWORDS

\ Mechatronics \ Virtual reality \ Mobility \ Rehabilitation.

ENTERPRISES

DESCRIPTION

Background

Assistmov's innovations are based on novel methods and technologies generated by merging robotics and virtual reality with physical medicine. These innovations were developed by the company founder during his 10 years of research at Rutgers University (NJ, USA).

Description of the products/services/technology

The company's first product ("Moonwalk") is a multipurpose rehabilitation platform for the legs. It enables the diagnosis and rehabilitation of balance disorders and rehabilitation in patients with gait disorders. The training and exercises performed on the "Moonwalk" are particularly well suited to the rehabilitation of subjects with neuromotor impairments, such as hemiplegics, spinal injury patients and Parkinson's disease sufferers.

Customer references/collaborations/highlights

A prizewinner in the French Ministry of Research's 2008 business plan competition for innovative companies. Technical development of the prototype. Collaboration with Professor Bussel at the Physical Medicine and Functional Rehabilitation Service at Garches Hospital.

Collaborations sought

Collaborations with academic labs and clinical departments on patient evaluations. Industrial collaborations for launching pre-series. Distribution agreements for the international and French markets.

→ 2 PATENTS

→ **STRENGTHS:** solid expertise in the creation of innovative, cost-effective technical aids which meet patient needs. The ambition to market industrializable solutions which improve quality of life for people with reduced mobility.

→ **INNOVATION ASSETS:** a multidisciplinary approach in robotics, computing and mechanical engineering.

Atragene Research Bioinformatics

FIELD OF ACTIVITY

\ ATRAGENE Research Informatics provides innovative industrial solutions for integrating, managing and sharing data and line-of-business applications.

KEYWORDS

\ Bioinformatics \ Cheminformatics \ Web \ Internet \ Software.

CEO \ Alain MALPERTUY

Contact details \ 33-35, rue Ledru-Rollin
F-94200 IVRY-SUR-SEINE
Tel \ +33 1 77 01 80 65
E-mail \ contact@atragene.com
Web site \ www.atragene.com
Date of founding \ 20th Nov. 2001

Atragene Research Bioinformatics offers pharmaceutical and biotech companies IT solutions for integrating, managing and sharing data and line-of-business applications. Our job consists in helping you plan and implement the right IT solution.

We offer our customers a range of professional services for:

- the design and implementation of IT solutions for integrating, visualizing and analyzing biological and chemical data.
- the implementation of line-of-business software (electronic laboratory notebooks, LIMS, etc.) to capture, manage and archive large amounts of data.

The benefits of ATRAGENE's high-value solutions include:

- The ability to access and share heterogeneous and dispersed data.
- Integrated and enhanced access to prediction and analysis tools.
- automation of the *in silico* analytical process.
- Information capture and storage.

Aurgalys

Associate Director \ Dr Philippe BERTHON

Contact details \ Pépinière Genopole® Enterprises
4, rue Pierre Fontaine - F-91058 Evry Cedex
Tel \ +33 1 60 87 89 66
E-mail \ contact@aurgalys.com
Web site \ www.aurgalys.com
Date of founding \ March 2008

FIELD OF ACTIVITY

\ Corporate finance: Aurgalys provides operational and/or strategic support to life science entrepreneurs and investors.

KEYWORDS

\ Corporate finance \ Business development \ Transition management \ Support \ Consulting.

DESCRIPTION

Background

As a scientist, manager and entrepreneur, Dr Philippe Berthon leverages his know-how and network of contacts. His career path has prompted him to think about the key issues in the life science sector. This means that Aurgalys provides solutions that truly meet the industry's needs.

Description of the products/services/technology

Transition management: CEO, CSO, regulatory affairs, CMO, marketing.
Business development: in/out licensing, joint ventures, distribution.
Corporate finance: fund raising, mergers & acquisitions, PIPE, alliances.
Support/consulting: strategy, due diligence, marketing.

Customer references/collaborations/highlights

Collaboration with the Israeli corporate finance provider Cukierman & Co Life Sciences.

→ Corporate finance: entrepreneurs serving entrepreneurs.

Bio Support

BIO SUPPORT

FIELD OF ACTIVITY

\ A not-for-profit organization for sharing personnel between several companies.

KEYWORDS

\ Human resources \ Sharing.

President \ Gregory LEMKINE
Director \ Noëlle COUGET

Contact details \ Pépinière Genopole® Enterprises
4, rue Pierre Fontaine - F-91058 EVRY Cedex
Tel \ +33 1 60 87 89 84
E-mail \ noelle.couget@biosupport.fr
Date of founding \ 23rd Nov. 2005

DESCRIPTION

Background

A not-for-profit organization founded in 2006 on the initiative of 6 Genopole® companies, with a view to sharing key employees whom individual members could not afford to recruit on a full-time basis.

Description of the products/services/technology

Shared human resources in finance, accountancy, quality management and IT.

Customer references/collaborations/highlights

24 member companies.

→ 4 SALARIED STAFF

Agdia Biofords

Manager & Scientific Director \ Marc MASSON
**In charge of Sales & Marketing **
Salima BERKANI \ Marcos AMATO

Contact details \ 5, rue Henri Desbruères - Genavenir 8
F- 91030 EVRY Cedex
Tel \ +33 1 60 78 81 64
E-mail \ info@biofords.com
Web sites \ www.biofords.com \ www.agdia.com
Date of founding \ 18th Nov. 1988

FIELD OF ACTIVITY

\ Diagnostic kits for plant disease, genes of interest, GMOs, growth hormones and hepatotoxins in water.

KEYWORDS

\ GMO detection \ Detection of toxins in water \ Rapid diagnostic kit \ Detection of plant diseases \ Agro-industry.

Background

BIOFORDS was created in 1988 by Marc Masson, a former CSO at the vegetable seed company CLAUSE (selection of potatoes, forage crops and lawn grasses) with research experience at the University of Wisconsin (Madison, USA).

Description of the products/services/technology

Development and commercialization of detection kits for:
- plant pathogens (viruses, bacteria, fungi, viroids and phytoplasma).
- genetically modified organisms (GMOs: sweet corn, soya, canola, etc).
- waterborne toxins (microcystins).
- plant growth hormones (auxins, abscissic acid, etc).

Customer references/collaborations/highlights

- Biobest NV, Belgium (www.biobest.be).
- INRA, including the URGV unit in Evry (France).
- Naktuinbouw, The Netherlands (www.naktuinbouw.nl).
- Serial Genetics, France (www.serialgenetics.com).
- universities and research institutes across Europe and the United States.

Collaborations sought

We offer personalized solutions to agrifood industry players.
- animal feed.
- production, storage and transformation of major crops (potato, sweet corn, cereals).
- horticulture, market gardening, nurseries, vineyards.

→ **ANNUAL TURNOVER 2007/2008: €821 K** → **1 PATENT** → **6 SALARIED STAFF**

→ **STRENGTHS:** plant diseases and plant genetics.
→ **INNOVATION ASSETS:** development of kits with novel antibodies.

The Biomanufacturing Center

Located at Genopole®

FIELD OF ACTIVITY

\ GMP custom biomanufacturing.

Project manager \ Alain MÉTAYER

Contact details \ Genopole® Campus 1
5, rue Desbruères Bâtiment G8 - F-91030 EVRY Cedex
Tel \ +33 1 60 87 35 16 \+33 6 88 63 83 32
E-mail \ alain.metayer@genopole.fr
Web site \ www.genopole.fr

DESCRIPTION

Genopole® has created a GMP Biomanufacturing Center on the Evry campus for animal cell-based production of recombinant proteins in general and monoclonal antibodies in particular.

As with other contract manufacturing organizations, the Center will custom-produce clinical batches for biotech companies and public-sector research laboratories and constitute an alternative to in-house biomanufacturing for big pharma.

Two independent cell culture rooms will enable the simultaneous production of 2 different biomolecules; one room will be dedicated to small batches (ranging from a few hundred mg up to a few tens of g) and the other will be able to handle batches of up to several hundred g. The Center will have the potential to manufacture 8 to 10 clinical batches a year.

The Center will use the latest technologies (notably single-use equipment) in order to keep production costs as low as possible. Operation of the facility will be subject to a strict quality management system according to European GMP.

Qualifications of the premises, the pharmaceutical utilities and the equipment is set to complete in the coming months; this will enable inspection by the AFSSAPS (the French Agency for Healthcare Product Safety) and customer audits from the end of 2009 onwards and the start of clinical batch production in early 2010.

The Center's initial commercial offering will include cell bank creation and process optimization, as well as production. Cell engineering, viral safety and aseptic dispensing services will be added soon afterwards.

Download the brochure on www.genopole.fr



Biomethodes

CEO \ Gilles AMSALLEM
CSO \ Bruno WINTER

Contact details \ Bâtiment Genavenir 1
1, rue Pierre Fontaine - F-91058 EVRY cedex
Tel \ +33 1 60 91 21 21
E-mail \ info@biomethodes.com
Web site \ www.biomethodes.com
Date of founding \ 6th Nov.1997

FIELD OF ACTIVITY

\ Genetic engineering applied to bioenergy, green chemistry and industrial biotech.

KEYWORDS

\ Biocatalysis \ Biofuels \ Biorefinery
\ Specialty enzymes.

ENTERPRISES

DESCRIPTION

Background

1998-2000: development of the company's technology platform.
2000-2005: R&D collaboration with several major chemicals and pharmaceutical companies.
2005-2007: development of biocatalysis and bioenergy applications.
2008-2011: collaboration between Biomethodes and Virginia Technology/Oak Ridge National Laboratory (US Department of Energy) on the development of the OPTAFUEL/OPTACHEM biorefinery platform.

Description of the products/services/technology

Genetic, protein and enzyme optimization. Biomanufacturing system applied to industrial biotech.

The company has developed and exploited novel technologies (MMT® and THR®) for improving industrial enzymes. These technologies are protected by 3 patent families owned by the company and parts of the work have been published in top-rank scientific journals.

Customer references/collaborations/highlights

Development of the first process for transformation of lignocellulosic biomass into cellulose, hemicellulose, lignin, acetic acid. Implementation of the enzymatic hydrolysis of biomass.

Collaborations sought

Joint ventures in industrial chemistry, energy and the environment.

→ 12 PATENTS → 12 SALARIED STAFF

→ **STRENGTHS:** intellectual property, industrial feasibility, well positioned in the USA and Europe.

BioQuanta

CEO \ **Jean-Michel MAUCLAIRE**
Manager \ **Thierry GÉRARDI**

Contact details \ 5, rue de l'abbé de l'Epée - F-75005 Paris
Tel \ +33 9 50 73 93 26 - Fax \ +33 1 46 33 14 24
E-mail \ contact@bioquanta.net
Web site \ www.bioquanta.net
Date of founding \ 2003

FIELD OF ACTIVITY

\ R&D services for the development of therapeutics and diagnostic kits. The MultiDIP™ *in silico* platform (ADMET prediction and characterization) and the Mitoxis™ *in vitro* platform (whole-metabolome exploration).

KEYWORDS

\ Service \ Toxicity \ Diagnostics \ Therapeutics \ R&D.

DESCRIPTION

Background

BioQuanta was founded in 2003 by a team of scientists and business professionals; the company's ethos can be summed up by "only a strong, global approach will result in an extensive range of new, sustainable therapeutics and theranostics".

Description of the products/services/technology

The MultiDIP™ and Mitoxis™ platforms are derived from technologies and tools used in clinical biology; they generate complementary data and information from the cellular level down to the atomic scale. The platforms are designed for pharmaceutical, cosmetics and agrifood companies or those concerned by the REACH legislation. From organic synthesis through to pharmacovigilance studies, the BioQuanta service platforms provide support for «go/no go» decisions in lead optimization & development and drug repositioning by maximizing cost savings and shortening timelines.

Customer references/collaborations/highlights

In parallel with B-to-B service contracts, BioQuanta collaborates with academic and hospital labs as part of its in-house research, in order to respond to the challenge of making decisive progress in science and healthcare. By committing to strong, wide-ranging science backed up by advanced technologies, BioQuanta's research has resulted in several patent filings in both the therapeutic and diagnostic fields.

Collaborations sought

Diagnostics companies for the production and distribution of patented kits.

→ **4 PATENTS** → **10 SALARIED STAFF**

→ **STRENGTHS:** an R&D service platform derived from clinical biology and which generates high-precision, reliable, complementary data and information from the cellular level down to the atomic scale. Multidisciplinarity. Collaboration with clinical researchers from the Paris Public Hospitals Group (AP-HP).
→ **INNOVATION ASSETS:** a dual approach: the MultiDIP ™ *in silico* platform (ADMET prediction and characterization) and Mitoxis™ in vitro platform (whole-metabolome exploration).
→ **OTHER FACTS:** R&D on diagnostic kits.

BioSolution



FIELD OF ACTIVITY

\ consultancy and service provision: a specialist in IT solutions for the integration, management and analysis of biological data.

KEYWORDS

\ LIMS \ Data management
\ Information systems \ Data analysis.

Director \ Guillaume KERBOUL

Contact details \ Pépinière Genopole® Enterprises,
4, rue Pierre Fontaine - F-91058 Evry Cedex
Tel \ +33 1 46 85 28 58
E-mail \ contact@biosolution.fr
Web site \ www.biosolution.fr
Date of founding \ 4th Oct 2006

Background

Since 2006, BioSolution has been providing support for all phases of IT system design and development. In 2009, BioSolution merged its business activities with those of SPLIMS (an exclusive LabVantage partner for French-speaking markets and a supplier of LIMS for research, clinical trials, quality control and production in many industrial sectors).

Description of the products/services/technology

- Lab automation, biological sample tracking and robot integration. Integration of high-throughput biological platforms.
- Deployment of life science information systems (document management systems, reporting systems, web portals, etc.).
- Design and development of scientific databases, data integration.

Customer references/collaborations/highlights

BioSolution specializes in the integration of heterogeneous biological data and is a Gold Partner for Talend Open-Source ETL solutions.

→ **STRENGHTS :** very good knowledge of biotech, computing expertise.
→ **INNOVATION ASSETS:** the use of open-source software bricks.

BioSystems International

CEO \ **Jean-Pierre TIROUFLET**
CSO, General director \ **Laszlo TAKACS**
CFO \ **Elisabeth ROCOLLE-TEYSSIER**

Contact details \ Pépinière Genopole® Enterprises
4, rue Pierre Fontaine - F-91058 EVRY Cedex
Tel \ +33 1 60 87 89 75
E-mail \ info@biosys-intl.com
Web site \ www.biosys-intl.com
Date of founding \ 17th May 2004

FIELD OF ACTIVITY

\ Research, validation and qualification of cancer biomarkers with the goal of developing products for diagnostics and research.

KEYWORDS

\ Biomarker \ Diagnostics \ Monoclonal antibody \ Plasma.

ENTERPRISES

DESCRIPTION

Background

BSI was founded in 2004 by 6 former members of Pfizer's genomics and bioinformatics division in Fresnes. The company now has a total of 30 employees based at the Evry Genopole® and in Hungary.

Description of the products/services/technology

Discovery and validation of cancer biomarkers and chronic diseases by using a proteomics technology platform based on proprietary, large-scale monoclonal antibody libraries. The antibodies are generated against human plasma proteins and then undergo high-throughput screening. The company also develops and commercializes cancer diagnostics based on panels of monoclonal antibodies.

Customer references/collaborations/highlights

The development and commercialization of Arrayit's PlasmaScan® arrays containing monoclonal antibodies against plasma proteins (for use as research tools).

Collaborations sought

BSI is seeking partners for the development, production and commercialization of cancer diagnostics generated in their in-house research programs.

→ 30 SALARIED STAFF

Cellvax

CELLVAX®
Drug Validation Expertise

FIELD OF ACTIVITY

\ Provider of innovative preclinical services (both *in vitro* and *in vivo*) for accelerating drug development (mainly in oncology) via the more accurate, rapid assessment of efficacy and safety.

KEYWORDS

\ Animal models \ Cancer \ Metastases \ Histological analysis \ Preclinical CRO.

CEO \ Dr. Ming WEI

Contact details \ Pépinière Genopole® Enterprises
4, rue Pierre Fontaine - F-91058 Evry France
Tel \ +33 1 60 87 89 57
E-mail \ contact@cellvax-pharma.com
Web site \ www.cellvax-pharma.com
Date of founding \ 19th June 2001

Background

Since its incorporation in 2001, Cellvax has developed its technology platform and signed contracts with a range of customers/partners worldwide.

Description of the products/services/technology

Cellvax's expertise in molecular biology, cell culture and novel animal models enable the company to offer stakeholders in the fight against cancer a range of custom services for the evaluation and development of drug candidates: models of subcutaneous and/or orthotopic tumors, *in vitro* and *in vivo* angiogenesis tests, a "nodule" system, tumor invasion, *in vivo* imaging, biodistribution, toxicity, pharmacokinetics, etc.
Cellvax's services are backed up by team of expert scientists and oncologists with complementary skills, giving the company a unique scientific, medical and industrial dimension. Its loyal customers, high-level partners and grants-in-aid from the European EUREKA program and the French state all testify to the quality of its service offering.

Customer references/collaborations/highlights

The growth in turnover since 2004 testifies to strong market demand and Cellvax's ability to continually meet its customers' needs.

Collaborations sought

In order to accelerate and expand its development, Cellvax is actively seeking new customers and/or public or private-sector partners from the pharmaceutical and biotech sectors. Cellvax guarantees confidentiality, high-quality services and responsiveness within the framework of its collaborations.

→ ANNUAL TURNOVER: €500 K → 5 SALARIED STAFF

→ **STRENGTHS:** a comprehensive, innovative technology platform: *in vitro*, *in vivo* and histological tools; our models of subcutaneous and orthotopic tumors with metastasis formation and chemotherapy resistance.

Cellvir S.A.S.

CEO \ **Michael COURTNEY**
CSO \ **Richard BENAROUS**

Contact details \ Pépinière Genopole® Enterprises
4, rue Pierre Fontaine - F-91058 EVRY Cedex
Tel \ +33 1 60 87 89 00
E-mail \ michael.courtney@cellvir.com
Web site \ www.cellvir.com
Date of founding \ March 2006

FIELD OF ACTIVITY

\ CellVir has set itself the goal of developing a new generation of antiviral agents based on an innovative, proprietary scientific approach.

KEYWORDS

\ Antivirals \ HIV \ Drug discovery.

DESCRIPTION

Background

CellVir was spun out of the Cochin Institute's Virology Laboratory (headed by Richard Benarous), which has identified many cell cofactors that are essential for HIV replication. These co-factors constitute novel targets for the development of a new generation of antivirals.

Description of the products/services/technology

CellVir's first program covers the design and development of antiretrovirals which will overcome the limitations of currently available anti-HIV drugs, i.e. viral resistance, viral persistence and toxicity. An anti-HIV candidate with strong antiviral activity against a resistant HIV strain is being developed. The regulatory preclinical studies will complete in late 2010, with a view to a first-in-man, proof-of-concept study in 2011.

Customer references/collaborations/highlights

- leads and back-up series are under development.
- two patents filed on novel classes of anti-HIV molecules.
- licensing agreements on patents covering new antiviral targets.
- a seed funding round with the INSERM Transfer Initiative and G1J-IdF funds.

Collaborations sought

Partners for the co-development of anti-HIV products.

→ 6 PATENTS FAMILIES → 6 SALARIED STAFF

→ **STRENGTHS:** new product – new mechanism of action. Products that meet a market need.
→ **INNOVATION ASSETS:** new approach = innovative products.

Centaure Metrix

FIELD OF ACTIVITY

\ Centaure Metrix produces and sells diagnostic and therapeutic devices for gait disorders, with applications in medicine (rehabilitation, physical medicine, neurology, myology, geriatrics, rheumatology, etc.) and sports training.

KEYWORDS

\ Medical equipment \ Gait \ Rehabilitation.

CEO \ Dr Bernard AUVINET
CSO \ Dr Eric BARREY

Contact details \ Pépinière Genopole® Enterprises
4, rue Pierre Fontaine - F-91058 Evry
Tel \ +33 1 60 87 89 71 Fax \+33 1 60 87 89 99
E-mail \ direction@centaure-metrix.com
Web site \ www.centaure-metrix.com
Date of founding \ 18th Oct. 2001

DESCRIPTION

Background

Founded in 2001 by a scientist and a rheumatologist. A prizewinner in the French Ministry of Research's business plan competition for innovative companies and a member of the *Entreprendre* network and the Medicen Paris Region cluster.

Description of the products/services/technology

- -LOCOMETRIX diagnostics: solutions for evaluating and quantifying gait disorders and running style and performance; assessment of the risk of falls in the elderly.
- LOCOMETRIX feedback training: a treadmill-based, active rehabilitation method.
- LOCOMETRIX podology: a solution for evaluation the comfort of soles.
- EQUIMETRIX: a solution for quantifying locomotor parameters in four-legged animals: limps and fitness for racing.

Customer references/collaborations/highlights

Centaure Metrix is actively involved in clinical studies with the Pierre Fabre group (fibromyalgia, hyaluronic acid), the *Institut de Myologie* (human, canine and feline muscular dystrophies), Liege University Medical Center (Alzheimer's disease) and the Pays de la Loire University Medical Center (the PREPA study on prediction of the risk of falls in the elderly).

Collaborations sought

Research partners: evaluation of the risk of falls in the elderly, early detection of Alzheimer's disease, clinical evaluation of therapies for Parkinson's disease. Commercial partners: healthcare companies, mutual health insurers, distributors.

→ **ANNUAL TURNOVER: €140-186 K** → **1 PATENT** → **3 SALARIED STAFF**

→ **STRENGTHS:** a leader in accelerometry-based gait analysis. Solid scientific and clinical validations of the technology.
→ **INNOVATION ASSETS:** rapid results, portable equipment and applicable in routine practice.

DNA Therapeutics

CEO \ Jian-Sheng SUN

Contact details \ Pépinière Genopole® Enterprises
4, rue Pierre Fontaine - F-91058 Evry Cedex
Tel \ +33 6 24 75 32 39
E-mail \ contact@dna-therapeutics.com
Web site \ www.dna-therapeutics.com
Date of founding \ 8th June 2006

FIELD OF ACTIVITY

\ Development of a new class of siDNA-based cancer drugs as an adjuvant to radiotherapy and chemotherapy.

KEYWORDS

\ Cancer \ Treatment resistance \ DNA repair \ Signal interfering DNA (siDNA) \ Adjuvants to radiotherapy and chemotherapy.

DESCRIPTION

Background

DNA Therapeutics is a biopharmaceutical company that was spun out of several public-sector research institutes (the Curie Institute, CNRS, INSERM and the French National Natural History Museum).

Description of the products/services/technology

DNA Therapeutics is developing a new class of drugs which targets tumor resistance to conventional therapies. In fact, the efficacy of today's radio- and chemotherapies is often limited by the action of cellular DNA repair complexes, which are responsible for the appearance of treatment resistance.

Customer references/collaborations/highlights

In collaboration with public-sector research partners, DNA Therapeutics has obtained *in vivo* proof of concept of the efficacy of its first product (Dbait) as an adjunct to radiotherapy or chemotherapy. The company has elucidated Dbait's mechanism of action and identified a series of biomarkers. Dbait should move into the regulatory preclinical phase by the end of 2009 and go into the clinic by late 2010.

Collaborations sought

(i) a strategic alliance with a pharmaceutical company after the achievement of clinical proof of concept.
(ii) sublicensing and early co-development agreements with partners for defined geographic territories, in emerging markets or in animal healthcare.

→ 3 PATENT FAMILIES, INCLUDING 1 GRANTED IN THE USA → 7 SALARIED STAFF

→ **STRENGTHS:** adjuvant molecules for radio- and chemotherapy.
→ **INNOVATION ASSETS:** unique, patented, breakthrough technology that has been validated in the animal.

Drugabilis

DRUGABILIS
from molecules to drug candidates

FIELD OF ACTIVITY

\ Evaluation of drugability in early-phase R&D: experimental support and consultancy for the evaluation and selection of highly druggable candidates.

KEYWORDS

\ Early formulation \ Salts and polymorphism
\ Lead optimization
\ Selection of drug candidates \ Preformulation.

CEO & CSO \ **Joel VACUS**
COO \ **Isabelle MENIER**

Contact details \ 5, rue Jean-Baptiste Clément
F-92290 Châtenay-Malabry
Tel \ +33 1 46 61 28 50
E-mail \ contact@drugabilis.com
Web site \ www.drugabilis.com
Date of founding \ Oct. 2004

DESCRIPTION

Background

2006: accredited for France's research tax credit
2007: winner of the "Trophée Espoirs de l'Economie" award (*Hauts de Seine* Chamber of Commerce and Industry – 2nd prize)
2009: Drugabilis joins the Board of Directors at the Medicen Paris Region cluster

Description of the products/services/technology

DRUGABILIS studies the physical-chemical and biopharmaceutical profiles of new chemical entities and drug delivery systems via lead optimization programs, early formulation for animal studies, salt selection, preformulation and polymorphism studies. Drugabilis is the only French CRO to have this type of characterization platform for supporting early-stage research.

Customer references/collaborations/highlights

DRUGABILIS has already worked for more than 40 different customers including: Anaconda Pharma, Cytomics Pharmaceuticals, Genfit, Guerbet, Ipsen, Pfizer, Phenex Pharmaceuticals, Trophos, PreGlem, HRA Pharma and Mutabilis. The company is also a partner in the MODEXA collaborative project (funded by the Medicen Paris Region cluster).

Collaborations sought

DRUGABILIS offers its services to (i) biotech companies seeking to accelerate their research and secure the pharmaceutical development of their drug candidates and (ii) pharmaceutical companies looking for highly qualified, well-equipped and flexible subcontractors.

→ ANNUAL TURNOVER: €0.5 MILLION → 5 SALARIED STAFF

→ **STRENGTHS:** unique expertise in drugability at the research/development interface, a particularly comprehensive technology platform and very experienced staff. Micro-methods suited to the constraints of today's research programs. Novel methodologies, responsiveness, flexibility and rapid service.
→ **INNOVATION ASSETS:** the formulations developed for animal studies can be produced, characterized and dispatched in real time on the test site. Drugabilis' regular customers benefit from a special mode of interaction which accelerates day-to-day collaboration and research program support.

The Enzyme Production and Biocatalysis Center

Located at Genopole®

Due to open in late 2010

Project manager \ Alain MÉTAYER

Contact details \ Genopole® Campus 1
5, rue Desbruères Bât GenAvenir 8 -
F-91030 EVRY cedex
Tel \ +33 1 60 87 35 16
E-mail \ alain.metayer@genopole.fr
Web site \ www.genopole.fr

FIELD OF ACTIVITY
\ Industrial-scale production of proteins.

KEYWORDS
\ Biomanufacturing.

DESCRIPTION

The project's goal is to provide pharmaceutical, chemical, agrochemical and cosmetics companies with access to biotechnological processes which replace or complement conventional chemical approaches.

This development was prompted by two key industrial issues: the need to review and revise chemical processes for economic environment or regulatory reasons and the need to add value to co-products which currently go to waste, due to the lack of viable applications.

The industrial biotech company in charge of operating the biomanufacturing center is a specialist in synthetic biology and the construction of novel metabolic pathways as applied to compounds used in the specialty chemicals industry.

By discovering novel biocatalysts, the Center will enable to exploit the results of the systematic sequencing of microbial genomes performed by one of the project partners.

Furthermore, the center will have the capacity to develop innovative proprietary bioprocesses and implement kilogram-scale custom production for industrial customers.

In view of the time needed to fit out the premises and qualify the equipment, the Center is due to be commissioned in late 2010.

Epixis

CEO \ Charlotte DALBA, M.D., Ph.D.

Contact details \ 16-18, rue de la Glacière
F-75013 Paris
Tel \ +33 1 42 17 65 20
E-mail \ cd@epixis.com
Web site \ www.epixis.com
Date of founding \ 23rd July 2003

FIELD OF ACTIVITY

\ Epixis is developing vaccines based on a new generation of virus-like particles (called "e-VLPs") targeting infectious agents. Epixis also acts as a service provider for serum screening (neutralizing antibody assays).

KEYWORDS

\ VLP \ Vaccine \ DNA vaccine \ Infectious disease \ Neutralizing antibody.

ENTERPRISES

DESCRIPTION

Background

Since 2004, Epixis has:
- put together a world-class group of specialist staff.
- built a portfolio of five patent families (based on IP from the CNRS, INSERM, the Pierre & Marie Curie University of Paris and the Pasteur Institute) covering a vaccine technology which is applicable to many different infectious diseases.
- validated the e-VLP platform in hepatitis C.
- established a unique serum screening service platform.

Description of the products/services/technology

Epixis has developed the e-VLP technology platform for vaccine production. The e-VLP platform combines the efficacy of VLPs (such as those used in Gardasil® and Cervarix® vaccines) with a much greater degree of flexibility in particle design. Whereas first-generation VLPs used proteins which had to be capable of self-assembly, Epixis' e-VLPs can potentially express all types of viral envelope proteins. The e-VLPs replicate the natural virus perfectly and thus induce an appropriate immune response.

Customer references/collaborations/highlights

The first vaccine candidate (a therapeutic vaccine for hepatitis C) has been validated in the mouse and the monkey and is ready to start regulatory preclinical development.

Collaborations sought

Epixis is seeking partners to lead the preclinical and Phase I/IIa clinical development of its first vaccine candidate and to apply the e-VLP technology to a second infectious disease.

→ ANNUAL TURNOVER: €544 451 → 5 PATENTS → 7 SALARIED STAFF

→ **STRENGTHS:** a team with acknowledged expertise, a solid patent portfolio. A unique technology platform that is applicable to many infectious diseases, including some with very significant markets.
→ **INNOVATION ASSETS:** e-VLPs combine the efficacy of VLPs (such as those used in Gardasil® and Cervarix® vaccines) with a much greater degree of flexibility in particle design.



Flowgene

CEO \ Bruno de VANDIERE

Contact details \ Rond Point du Biopole
F-63360 Saint Beauzire
Tel \ +33 4 73 64 43 69
E-mail \ b.de.vandiere@flow-gene.com
Web site \ www.flowgene.com
Date of founding \ 11th Dec. 2001

FIELD OF ACTIVITY

\ Analytical instrumentation: detection of laser-induced native and/or Raman fluorescence.

KEYWORDS

\ Fluorescence \ 224 nm laser \ HPLC \ Capillary electrophoresis \ Odor detection.

ENTERPRISES

DESCRIPTION

Background

- 2003: filing of a patent on the use of an elliptical cell to collect a fluorescence signal.
- 2005: filing of a patent for the detection of odors (detection of a conformational change in a protein).

Customer references/collaborations/highlights

- a development contract with the US Department of Defense on an odor detector.
- a development contract on a capillary electrophoresis detector.

Description of the products/services/technology

- odor detector (2006).
- the HPLC 224 LINF detector (2008).
- capillary electrophoresis detector (2008).

Collaborations sought

- the detection, identification and counting of bacteria in suspension.

→ ANNUAL TURNOVER (2009): €500 K → 3 PATENTS → 2 SALARIED STAFF

→ **STRENGTHS:** in-depth knowledge of laser-induced native the Raman fluorescence (with a 224 nm laser). Strong patent position.
→ **INNOVATION ASSETS:** the only company to have mastered this detection technology.
→ **OTHER FACTS:** a second-generation detection cell is being developed.

GeneSignal

FIELD OF ACTIVITY

\ Based on its portfolio of over 90 genes specifically involved in angiogenesis, Gene Signal designs, validates and develops innovative therapeutic solutions for pathologies related to angiogenesis regulation.

KEYWORDS

\ Rejection of corneal grafts \ Anti-angiogenics \ Antisense oligonucleotide \ Retinopathy \ Oncology.

CSO \ Salman AL-MAHMOOD

Contact details \ Pépinière Genopole® Enterprises
4, rue Pierre Fontaine - F-91058 Evry Cedex
Tel \ +33 1 60 87 89 41/89 35
E-mail \ sam@genesignal.com
Web site \ www.genesignal.com
Date of founding \ 11th Feb. 2000

DESCRIPTION

Background

GeneSignal was founded in 2000 at Genopole®. Although GeneSignal International is now based in Switzerland, the company is pursuing its research program in Evry and its development activity in Canada.

Description of the products/services/technology

GeneSignal is focusing its development on niche markets. Its first drug candidate (for the prevention of corneal graft rejection) is in Phase III clinical development. The company is evaluating three other drug candidates with applications in dermatology and ophthalmology and is also working on four promising molecules in the field of vascular disease.

Collaborations sought

In order to focus on research, GeneSignal is currently seeking potential licensees for commercializing or co-developing its therapeutic portfolio..

Genethon

President \ Laurence TIENNOT-HERMENT
Secretary General \ Stéphane ROQUES

Contact details \ 1 bis, rue de l'Internationale - BP 60 - F-91002 EVRY Cedex
Tel \ +33 1 69 47 28 28
E-mail \ sroques@genethon.fr
Web site \ www.genethon.fr
Date of founding \ 1990

FIELD OF ACTIVITY

\ Discovery, development and manufacture of innovative therapeutics for rare genetic diseases, (notably neuromuscular diseases)

KEYWORDS

\ Rare diseases \ Gene therapy, cell therapy \Therapies based on genetic knowledge \ Drug targeting techniques, gene transfer, stem cells, pharmaceutical development, regulatory affairs, preclinical and clinical development (*in vitro* and *in vivo* experiments, imaging, functional studies, therapeutic evaluation) \ GMP production of gene transfer vectors (in the ETGC Gene and Cell Therapy Unit).

DESCRIPTION

Since 1997, Genethon, a biotherapeutics company (more than 90% funded by the AFM, the French Muscular Dystrophy Association, via donations raised during the French «Telethon» TV fundraising event), has focused on gene & cell therapies and their applications in rare genetic diseases.

Genethon's activity encompasses:

- a GMP-certified biomanufacturing unit for the production and release of clinical trial batches.

- pharmaceutical development activity, the goal of which is to establish reliable, reproducible and upscalable processes which comply with the current legislation and safety requirements.

- drug development activity generated by both in-house and collaborative research: Duchenne and limb-girdle muscular dystrophies, Wiscott-Aldrich syndrome, epidermolysis bullosa, etc.

- clinical research activity (the design, funding and performance of clinical trials);

- research activity (performed in collaboration with the CNRS*, the INSERM and the University of Evry) (see p.26)

*the French National Center for Scientific Research (the joint CNRS/ Université d'Evry research unit 3018).

→ 8 PATENTS → 24 SCIENTIFIC PUBLICATIONS → 199 SALARIED STAFF

→ **STRENGTHS:** 1st gene therapy batch produced in 2008 and released in 2009 for a forthcoming clinical trial in Wiskott-Aldrich syndrome.

Genewave



FIELD OF ACTIVITY

\ Genewave develops, produces and commercializes microarray consumables and instruments for genomics, proteome analysis and medical diagnostics.

KEYWORDS

\ Diagnostics \ Biochips \ Microarrays \ DNA.

President \ François-Xavier DESFORGES
Chief Executive \ Houtaï CHOUMANE

Contact details \ XTEC – Bâtiment 404
Campus Ecole Polytechnique - F-91128 PALAISEAU Cedex
Tel \ +33 1 69 33 15 75
E-mail \ info@genewave.com
Web site \ www.genewave.com
Date of founding \ Dec. 2001

DESCRIPTION

Background

Genewave (founded in 2001) develops, produces and commercializes consumables and instruments for genomics, proteome analysis and medical diagnostics. More specifically, we offer a range of DNA microarrays and readers. Our innovative solutions improve the performance of existing systems (in terms of automation and reliability) for genetic analysis and medical diagnostics.

Description of the products/services/technology

The company's 25 staff (including 10 PhDs) have a unique set of core skills in optics, biology, chemistry, electronics and computing.

Genewave offers its customers:

- AmpliSlide™: reflective slides for high-sensitivity arrays.
- Diagarray™: a compact reader for multipatient microarrays.
- HybLive™: an integrated microarray hybridization and real-time reading system. HybLive™ is an open platform capable of analyzing standard microarrays and high-sensitivity Amplislides™.
- integrated robots for molecular diagnostics.

Collaborations sought

Molecular diagnostics manufacturers.

→ 25 SALARIED STAFF

GenOdyssee

CEO \ Jean-Louis ESCARY

Contact details \ Pépinière Genopole® Enterprises
4, rue Pierre Fontaine - F-91030 EVRY Cedex
Tel \ +33 6 16 41 68 57
E-mail \ escary@genodyssee.com
Web site \ www.genodyssee.com
Date of founding \ 1999

FIELD OF ACTIVITY

\ Discovery and development of therapeutic proteins via a proprietary process resulting from knowledge of the human genome. Infectious disease and immunotherapy.

KEYWORDS

\ Biopharma \ Therapeutic proteins \ Infectious diseases \ Cancer \ Vaccines.

DESCRIPTION

Background

1999-2008: €20 million in funds raised.
Turnover: €2.2 million
2005-2008: transition to a virtually integrated pharmaceutical company (VIPCO). R&D process.

Description of the products/services/technology

GenOdyssee operates a proprietary technology platform for the discovery of natural variants of blockbuster human therapeutic proteins with improved therapeutic indices. This technology has already been applied to cytokines and growth factors but can be extended to all other therapeutic proteins. GenOdyssee is developing a pipeline of products, including 2 proprietary variants of human interferons for applications in virology (improvement of hepatitis C treatments) and immunotherapy (cancer and vaccines), as well as a proprietary variant of human alpha erythropoietin (EPO).

Customer references/collaborations/highlights

GenOdyssee has a broad, global and well-balanced intellectual property portfolio, with a total of 53 granted and pending patents in 17 countries. After the first biotech industry boom (which validated the "from the human protein to the drug" approach), GenOdyssee is the first company to have validated the «gene-to-drug» concept and identified new drugs directly on the basis of human genome analysis.

Collaborations sought

GenOdyssee is looking for strategic collaborations with the pharmaceutical industry, focusing on the development of an initial portfolio of products and the potential of the company's proprietary discovery engine for novel therapeutic proteins.

→ **ANNUAL TURNOVER (1999-2008): €2.2 MILLLION** → **33 PATENTS**

→ **STRENGTHS:** an international management team; strong, worldwide IP coverage; large, high-growth target markets; organizational flexibility; healthy finances and rigorous financial management. The only high potential approach for the improvement of key therapeutic proteins; failure of the international competition (who use improvement methods based on artificial mutations).
→ **INNOVATION ASSETS:** the first genomics company to have validated the "gene-to-drug" approach in humans.

Genomining



FIELD OF ACTIVITY

\ Genomining specializes in the discovery and interpretation, of data in biology for the life science industry.

KEYWORDS

\ Bio-informatics \ Life science databases \ Data mining in genetics \ Genomics \ Postgenomics.

CEO \ William SAURIN

Contact details \ 4, rue René Barthélémy
F-92120 MONTROUGE
Tel \ +33 1 42 31 08 08
E-mail \ info@genomining.com
Web site \ www.genomining.com
Date of founding \ 24th April 2001

Background

Genomining was the scientific leader of the Decrypthon I project in 2001-2002 (a major grid computing protein comparison project), together with AFM and IBM and assistance from 75,000 volunteers on the internet.

Description of the products/services/technology

Genomining develops and markets tools which help analyze data in biology;

- GetDB, which allows automatic database downloading and integration, whatever the data's original format;
- Navibio, which integrates all the functions needed to automate and facilitate access to a large set of molecular biology databases;
- UVSS, which manages large «virtual screening» pipelines.

Genomining also offers consultancy on bioinformatics.

Genoplante Valor

**Member of the Executive Board **
Dominique LABORDE

Contact details \ 523, place des Terrasses
F-91034 EVRY Cedex
Tel \ +33 1 69 47 54 00
E-mail \ laborde@genoplante.com
Web site \ www.genoplante.com
Date of founding \ 7th Nov. 2001

FIELD OF ACTIVITY
\ Plant genomics.

KEYWORDS
\ Research exploitation
\ Agro-industry \ Plant genomics.

Background

Genoplante-funded programs have generated (and continue to generate) a large body of research results that have been published as scientific articles, posters, etc. and have thus contributed to the extension of scientific knowledge.

Many of these results concern patented technologies, bioinformatics tools, biological material (bacterial artificial chromosome (BAC) libraries, for example), genetic markers, collections of mutants and other plant-based materials and are very widely available.

Description of the products/services/technology

Management of the intellectual property and exploitation of the research results generated in the Genoplante® plant genomics program (IP protection, patenting, license management, etc.). Bioinformatics and genomic resources for both model plants (Arabidopsis and rice) and crop plants (corn, wheat, canola, peas, sunflower): integrated databases, annotation software, prediction software, etc.

Expressed sequence tags, microarrays (notably for Arabidopsis, rice, corn and wheat), markers, biological materials (BAC libraries), genome sequences (genes, promoters, etc.).

Customer references/collaborations/highlights

http://urgi.versailles.inra.fr

GenOptics



A division of

FIELD OF ACTIVITY

\ Design and manufacture of scientific instruments for the analysis of biomolecular interactions using surface plasmon resonance imaging (SPRi). Expert analysis and service provision in biomolecular analysis.

KEYWORDS

\ SPRi \ Label-free \ Bio-interaction \ Multiplexing.

CEO \ Didier-Luc BRUNET

Contact details \ GENOPTICS SA (HORIBA Scientific)
Tel \ +33 1 69 35 87 86
E-mail \ contact@genoptics-spr.com
Web site \ www.genoptics-spr.com
Date of founding \ 27th Aug. 2001

DESCRIPTION

Background

GenOptics was founded in 2001 as a result of work performed at the Optics Institute in Orsay and the French Atomic Energy Commission (CEA) in Grenoble. In April 2009, the company became a subsidiary of HORIBA Jobin Yvon, which is based in Longjumeau (near Paris).

Description of the products/services/technology

GenOptics's two systems (SPRi-Plex and SPRi-Lab+) provide the performance levels and flexibility that life science specialists expect. GenOptics also sells a range of consumables, such as biochips. A service activity is also available, in order to meet intermittent requirements for SPR bio-analysis.

Customer references/collaborations/highlights

GenOptics has special collaborations with several R&D establishments, such as the French army's DGA department and the CEA. GenOptics works on biochips with several international groups. In terms of life science applications, GenOptics collaborates with the University of Evry and recently filed for a patent on the interfacing of SPRi with MALDI-TOF mass spectrometry, thus providing researchers with easier access to the identification and quantification of new biomarkers.

→ **ANNUAL TURNOVER: €600 K** → **3 PATENTS** → **10 SALARIED STAFF**

→ **STRENGTHS:** flexibility. Expert instrumentation skills for the study of biomolecular interactions. A multidisciplinary team of graduate and PhD scientists and engineers. An international distribution network.
→ **INNOVATION ASSETS:** SPRi-mass spec coupling.

GenoSafe

President \ **Didier CAIZERGUES**
Commercial Director \ **Vincent ZULIANI**
Study Director \ **Dr Muriel AUDIT**

Contact details \ 1, rue de l'Internationale
BP 40064 - F-91002 EVRY Cedex
Tel \ +33 1 69 47 11 57
E-mail \ contact@genosafe.com
Web site \ www.genosafe.com
Date of founding \ 3rd Sept. 2003

FIELD OF ACTIVITY

\ GenoSafe is a service company which specializes in efficacy and safety testing of biotherapeutics. We provide our customers with needs-specific support which meets regulatory requirements.

KEYWORDS

\ Gene transfer \ Gene therapy \ Cell therapy \ Vaccination.

ENTERPRISES

DESCRIPTION

Background

GenoSafe was incorporated in 2003 and became operational in 2004. Its two shareholders are Genethon and the French Muscular Dystrophy Association (AFM).

Description of the products/services/technology

From the research phase through to the clinic, GenoSafe offers true project support in study design, methodological development & validation and product testing in four main fields:
- molecular analyses (including biodistribution studies for gene transfer products).
- evaluation of immune responses.
- quality control of gene therapy products for preclinical and clinical use.
- follow-up of patients included in clinical trials.

GenoSafe has close links with the regulatory bodies, in order to lobby effectively on behalf of its customers.

Customer references/collaborations/highlights

- GenoSafe's European clientele is composed of biotech firms, pharmaceutical companies and academic labs.
- GenoSafe is a partner in various French and European collaborative projects.
- GLP compliance certificate.

Collaborations sought

Clients seeking a service company to evaluate the safety and efficacy of their products and which meets their expectations in terms of scientific & regulatory rigor and deadlines.

→ 12 SALARIED STAFF

→ **STRENGTHS:** in-depth scientific expertise in complementary fields of technology, personalized service, flexibility, ability to meet deadlines, GMP compliance, Biosafety Level 1-3 facilities.
→ **INNOVATION ASSETS:** customer support from the research phase through to the clinic.

GenoSplice technology

FIELD OF ACTIVITY

\ Bioinformatics service provision (gene expression, splicing) \ Biomarker discovery based on splicing events in breast cancer.

KEYWORDS

\ Splicing \ Bioinformatics \ DNA chips \ Biomarker \ Breast cancer.

Co-managers \ Pierre de la GRANGE
Marc RAJAUD

Contact details \ GenoSplice technology
Centre Hayem – Hopital Saint Louis
1, av Claude Vellefaux - F-75010 Paris
Tel \ +33 1 57 27 68 39/42
E-mail \ contact@genosplice.com
Web site \ www.genosplice.com
Date of founding \ 12/11/2008

DESCRIPTION

Background

The company has been spun out of the European Alternative Splicing Network of Excellence (EURASNET).

Description of the products/services/technology

GenoSplice has developed high-performance analysis tools for processing the data generated by transcriptomics techniques (DNA microarrays, exon skipping, gene tilling, high-throughput sequencing, etc.).

Services provided:-
- analysis of gene expression, including splicing;
- biological interpretation tools (interfaces, databases, etc.);
- custom bioinformatics services: signaling pathway analysis, motif searching, clustering, probe design for custom chips, etc.

Biomarker discovery based on splicing events.

Customer references/collaborations/highlights

- a prizewinner in the French Ministry of Research's 2008 business plan competition for innovative companies.
- funding from BIOCRITT and OSEO.
- a member of the Medicen Paris Region cluster.
- Collaborations: INSERM, IGR, Pasteur Institute, CNRS, Curie Institute, University of Kentucky, University of Cambridge, University of Newcastle.

Collaborations sought

Exon-scale gene expression studies and biomarker discovery.



Global Bioenergies

CEO \ Marc DELCOURT
Member of the Executive Board \ Philippe MARLIÈRE

Contact details \ Pépinière Genopole® Enterprises
4, rue Pierre Fontaine - F-91058 EVRY Cedex
Tel \ +33 1 60 87 89 00
E-mail \ info@global-bioenergies.com
Web site \ www.global-bioenergies.com
Date of founding \ 17/10/2008

FIELD OF ACTIVITY

\ Global Bioenergies is developing a process for transforming various renewable resources into octane.

KEYWORDS

\ Biofuel \ Bioenergy \ Renewable resources \ Octane.

DESCRIPTION

Background

Global Bioenergies was founded in 2008 by Marc Delcourt (CEO) and Philippe Marlière (the project's originator).

Description of the products/services/technology

The company's proprietary process for transforming renewable resources into octane has energy-yield, environmental and cost benefits.

Customer references/collaborations/highlights

Global Bioenergies is deploying its activities by interfacing them with unique expertise in metagenomic sequencing, cloning and synthetic biology at the CEA Genomics Institute in Evry.

The company recently announced the closure of its first, multimillion euro round of funding with Masseran Management, the venture capital subsidiary of the Caisse d'Epargne bank.

Collaborations sought

Global Bioenergies will seek to forge industrial collaborations on the implementation of a pilot plant in 2010.

I-STEM
Institute for Stem Cell Therapy and Exploration of Monogenic Diseases

FIELD OF ACTIVITY

\ Evaluation of the full therapeutic potential of all types of human stem cells (Stem cells from all sources) in the treatment of monogenic diseases. Set against this background, the group is particularly exploring substitutive cell therapies for degenerative diseases on one hand and the use of stem cell lines carrying pathological mutations as drug screening targets on the other.

KEYWORDS

\ Cell therapy - disease modelling - stem cells - monogenic diseases \ Screening.

Manager \ Marc PESCHANSKI

Contact details \ Inserm/UEVE UMR 861, I-STEM, AFM :
Genopole Campus 1 - 5, rue Henri Desbruères,
F-91030 Evry cedex
Tel \ +33 1 69 90 85 17
E-mail \ lgrannec@istem.genethon.fr
Web site \ www.istem.eu
Date of founding \ January 2005

DESCRIPTION

Background

I-STEM (founded in 2005 by Marc Peschanski) is a R&D center dedicated to the elaboration of stem cell-based treatments for (amongst other things) rare genetic diseases. I-STEM is located at the heart of the Genopole® biopark and has been spun out of a collaboration between the French Muscular Dystrophy Association (AFM), the French National Institute for Health and Medical Research (INSERM) and the University of Evry-Val-d'Essonne.

Description of the products/services/technology

I-STEM is developing 9 research themes:
- neurodegenerative diseases (cell therapy, modeling of Huntington's disease)
- neuromuscular diseases (disease modeling of myotonic dystrophy)
- motor neuron diseases (molecular and cell mechanisms involved in the development of motor neuron diseases such as myotonic dystrophy)
- neurovascular damage (disease modeling and cell therapy)
- retinopathies and neural development diseases (cell therapy, disease modeling)
- genodermatoses (disease modeling of Clouston syndrome)
- biotechnology of human ESCs (mass production of cells, genetic engineering and high-throughput screening)
- high-throughput screening
- functional genomics (development of dedicated technological tools for the study of monogenic diseases).

Customer references/collaborations/highlights

French National Research Agency projects, Medicen Paris Region cluster projects, intercluster projects and European Union programs.

Collaborations sought

Industrial collaborations.

→ OPERATING BUDGET: €7 MILLION → 4 PATENTS → 76 SALARIED STAFF

Imagene

CEO \ Sophie TUFFET

Contact details \ Headquarters \ Parc Scientifique Unitec 1 - 2, allée du Doyen Brus - F-33600 Pessac
Branch office \ Immeuble GenAvenir 6 - Genopole® Campus 1 5, rue Henri Desbruères - F-91030 EVRY Cedex
Tel \ +33 1 60 77 62 22
E-mail \ imagene@imagene.fr
Web site \ www.imagene.fr
Date of founding \ 1st Dec. 1998

FIELD OF ACTIVITY

\ Services and products for long-term DNA storage at room temperature using encapsulation
\ Complementary DNA extraction services
\ R&D on the preservation of biological material at room temperature.

KEYWORDS

\ DNA storage \ Room temperature \ Long-term \ Industrial process \ Gene library.

ENTERPRISES

DESCRIPTION

Background

IMAGENE has developed and obtained a worldwide patent for a novel, encapsulation-based technology for the unlimited-term conservation of DNA at room temperature.

Description of the products/services/technology

The IMAGENE technology is based on controlled-atmosphere encapsulation of pre-purified and desiccated DNA which is then protected from degradation factors by storage in compact, sealed, corrosion-proof metal capsules. It is thus possible to store the DNA of any species in a form compatible with any type of current or subsequent analysis.

Our breakthrough innovation has many advantages over conventional (cryostorage) methods, particularly in terms of stability, safety, operating & maintenance costs, transport and distribution.

Customer references/collaborations/highlights

- an industrialized, automated technology platform applicable to the large-scale treatment of genetic material (2,500 DNA capsules a day, i.e. 500,000 a year).
- ensures full, lasting traceability of each biological sample and meets quality standards (ISO 9001: 2000, ISO 17025).
- many scientific collaborations, including the Institut Bergonie, the Pasteur Institute, the French National Natural History Museum and the French National Crime Research Institute (IRCGN).

Collaborations sought

With its encapsulation facility now operational, Imagene is seeking partners and customers (academic labs, biotech firms and pharmaceutical laboratories) interested in taking advantage of room temperature storage for their DNA samples.

→ 4 PATENT FAMILIES, 3 OF WHICH WERE FILED IN 2008 → 12 SALARIED STAFF

→ **STRENGTHS:** the only technology for stable DNA storage at ambient temperature.
→ **INNOVATION ASSETS:** compatible with all types of DNA analysis and handling methods.

InGen BioSciences



FIELD OF ACTIVITY

\ InGen BioSciences is developing a new approach to multiplexed blood testing for the diagnosis of human infectious diseases.
The firm also distributes a range of third-party diagnostics.

KEYWORDS

\ Antigens \ Serology \ Multiplexed diagnostics.

CEO \ Jean Pierre HERMET

Contact details \ 17, avenue du parc
F-91380 Chilly Mazarin
Tel \ +33 1 69 79 64 80
E-mail \ jph@ingenbiosciences.com
Web site \ www.ingenbiosciences.com
Date of founding \ 28/11/2001

DESCRIPTION

Background

InGen Biosciences was founded in 2001 as AbAg and raised funds in 2003 and 2005. The latter €6 million round of funding enabled the company to acquire InGen (a medical diagnostics distributor) in 2006.

Description of the products/services/technology

InGen Biosciences focuses on the discovery of new bacterial antigens by leveraging technological progress in proteomics. These antigens serve as the raw materials for the development of new-generation diagnostic kits. InGen sells and distributes medical diagnostics and is notably the French leader in HLA typing.

Customer references/collaborations/highlights

Our first product (BJI InoPlex) is being prototyped. It enables the diagnosis and monitoring of staphylococcal prosthetic joint infections.

Collaborations sought

We are looking for (i) new distribution agreements for our InGen subsidiary and (ii) collaborations for evaluating the performance of our antigens and completing our panel of antigens.

→ **ANNUAL TURNOVER: €16.8 MILLION** → **22 PATENTS FILED** → **62 SALARIED STAFF**

→ **STRENGTHS:** innovative antigens for serodiagnostics. Active R&D and a powerful distribution organization (a solid business model).
→ **INNOVATION ASSETS:** multiplexed serodiagnostic tests.

InnaVirVax

CEO \ Joël CROUZET, Ph.D.

Contact details \ Pépinière Genopole® Enterprises - CAMPUS 1- 4, rue Pierre Fontaine - F-91058 EVRY Cedex
Tel \ +33 1 80 85 60 86
E-mail \ contact@innavirvax.fr
Web site \ www.innavirvax.fr
Date of founding \ March 2008

FIELD OF ACTIVITY

\ InnaVirVax is developing (i) innovative biotherapies for the treatment of HIV infections and cancer and (ii) a prognostic test for the appearance of AIDS in seropositive patients.

KEYWORDS

\ HIV \ AIDS \ Vaccine \ Biotherapies \ Prognosis.

Background

InnaVirVax's projects have been spun out of the UMR-S 945 Immunity and Infection Laboratory (a joint INSERM-Pierre & Marie Curie University of Paris research unit) at the Pitié Salpêtrière University Medical Center. InnaVirVax was founded by Professor Patrice Debré, Vincent Vieillard and Joël Crouzet in order to develop new anti-HIV therapies on the basis of a breakthrough scientific discovery. InnaVirVax is also developing a novel biotherapy in the field of cancer.

Description of the products/services/technology

InnaVirVax is developing 4 products:
- a prognostic test for the prediction of immunodepression in HIV patients.
- a therapeutic vaccine for preventing the appearance of AIDS by maintaining HIV-1 patients in an asymptomatic state.
- a passive immunotherapy for immunodeficiency in treatment-failure VIH-1 patients.
- an innovative cancer immunotherapy.

Customer references/collaborations/highlights

InnaVirVax was a prizewinner in the French Ministry of Research's 2008 business plan competition for innovative companies. Furthermore, InnaVirVax has obtained a grant-in-aid from the French National Research Agency as part of the BiotecS program on therapeutic HIV vaccines.

Collaborations sought

InnaVirVax is seeking industrial partners (in the vaccines, biotherapies and diagnostics sectors) with the ability to pursue the development of InnaVirVax's projects.

→ 2 PATENTS FAMILIES FROM THE INSERM AND THE PARIS PUBLIC HOSPITALS GROUP (AP-HP) → 2 SALARIED STAFF

→ **STRENGTHS:** developing the applications of a breakthrough innovation.
→ **INNOVATION ASSETS:** the company's development products address unmet needs.

Integragen

FIELD OF ACTIVITY

\ IntegraGen identifies genetic variants associated with polygenic diseases (autism, metabolic syndrome, obesity, diabetes and cancer) and developing diagnostic tools.

KEYWORDS

\ Autism \ Metabolism \ Diagnostics \ Genetics.

CEO \ Bernard COURTIEU

Contact details \ Genopole® Campus 1
5, rue Henri Desbruères - F-91030 Evry
Tel \ +33 1 60 91 09 00
E-mail \ contact@integragen.com
Web site \ www.integragen.com
Date of founding \ 11th July 2000

DESCRIPTION

Background

IntegraGen was founded in 2000 on the basis of a locus identification technology for familial, polygenic diseases. The company rapidly built a portfolio of patents protecting its discoveries in the field of genetic predispositions.

Description of the products/services/technology

-IntegraGen offers genetics services (sequencing and genotyping) to research organizations on a CRO basis.
- diagnostics: IntegraGen develops panels of biomarkers likely to indicate an increased risk of disease appearance (in autism, notably). This enables early diagnosis and treatment.

Customer references/collaborations/highlights

-A license agreement with Siemens Molecular Diagnostics in the USA.
- service contracts with Servier.

Collaborations sought

Pharmaceutical co-development in metabolic diseases (diabetes/obesity) and CNS diseases.

→ ANNUAL TURNOVER: €2.2 MILLION → 25 PATENTS → 22 SALARIED STAFF

→ **STRENGTHS:** a full range of genetics platforms. Validated diagnostic tools.
→ **INNOVATION ASSETS:** IntegraGen's HIPTM technology.

LTKfarma

President \ Evence-Charles COPPEE
Business Development \ Dorothée CARVALLO
Scientific founders \ David KLATZMANN - François LEMOINE - Dr José COHEN

Contact details \ Pépinière Genopole® Enterprises
4, rue Pierre Fontaine - F-91058 EVRY Cedex
Tel \ +33 6 08 97 78 51
E-mail \ ltkfarma@neuf.fr
Web site \ www.ltkfarma.fr
Date of founding \ March 2006

FIELD OF ACTIVITY

\ Development and marketing of cell therapy products (derived from modified T-cells) for the treatment of leukemia and of certain auto-immune diseases and solid tumors.

KEYWORDS

\ Cell Therapy \ T lymphocyte \ Suicide gene \ GvHD \ Allograft.

DESCRIPTION

Background

LTKfarma is a biotech start-up that was spun out of research performed at the "Biology and Therapy of Immune Diseases» laboratory (a joint CNRS/Pierre & Marie Curie University of Paris research unit) and the Biotherapy Division at the Pitié-Salpêtrière Hospital.

Description of the products/services/technology

LTKfarma modifies the donor's T lymphocytes in vitro via the introduction of a "suicide gene" (TK-54). This enables post-graft cell selection.

1. Drastically reduce mortality from graft-versus-host disease (GVHD), the main complication of allogeneic, hematopoietic stem cell transplantation (HSCT), i.e. a target figure of 5% instead of today's 20%-60%.
2. Offer HSCT as a therapeutic alternative with an enhanced risk/benefit ratio for patients suffering from solid tumors and severe forms of autoimmune diseases such as scleroderma, multiple sclerosis and rheumatoid arthritis.

Customer references/collaborations/highlights

ÀTo date, TK-54 has been tested in Phase I/II clinical trials for the treatment of hematological cancers, with funding from the company's partners, the Paris Public Hospitals Group (AP-HP) and the French Muscular Dystrophy Association (AFM). LTKfarma was a top prizewinner in the French Ministry of Research's 2005 business plan competition for innovative companies, obtaining a €450,000 grant-in-aid.

Collaborations sought

The company is currently seeking industrial and commercial partnerships for the development and commercialization of its TK54 product
In parallel, the company has committed to finding financial partners which will enable it to pursue its regulatory and clinical efforts, with the goal of obtaining its first product marketing approval in 2012/2013.

→ 31 PATENTS IN 6 DIFFERENT FAMILIES → 2 SALARIED STAFF

→ **STRENGTHS:** an experienced team and strong IP.
→ **INNOVATION ASSETS:** the company's patented "suicide gene" technology.

MAT Biopharma

MATBIOPHARMA
IMMUNO TARGETING COMPANY

FIELD OF ACTIVITY

\ MAT Biopharma specializes in the development of monoclonal antibodies for therapeutic use, essentially in oncology.

KEYWORDS

\ Monoclonal antibody \ Oncology.

CEO \ François VALLET

Contact details \ Genopole® Campus 1
5, rue Henri Desbruères - F-91030 Evry Cedex
Tel \ +33 1 60 91 78 80
E-mail \ f.vallet@matbiopharma.fr
Web site \ www.matbiopharma.fr
Date of founding \ 15th Feb. 2000

DESCRIPTION

MAT develops monoclonal antibodies coupled to anti-angiogenic, anti-proliferative or cytotoxic compounds (such as ADCC or CDC).

MAT's product portfolio is in preclinical development:
- A chimeric gamma-4 anti-CD44 monoclonal antibody (Hyaloxan®) for the treatment of acute myeloblastic leukemia.
- A chimeric gamma-1 monoclonal antibody (anti-CD71) for the treatment of metastatic melanoma and choroid melanoma.
- A chimeric gamma-1 monoclonal antibody (anti-CD160) with anti-angiogenic activity (applications in solid tumors and ophthalmology).
- A bi-specific monoclonal antibody (anti-CD5/anti-CD32) for the treatment of chronic lymphoid leukemia.

MAT is also developing a Yttrium-90-coupled polyclonal antiferritin antibody (Ferritarg® P) for the radioimmunotherapy of refractory Hodgkin's disease. Ferritarg obtained orphan medicinal product status for this indication from the EMEA in 2004 and from the FDA in 2006, and has just completed a Phase I/II clinical trial. The protocol for a pivotal Phase III trial (which should enable product marketing approval) has been validated by the EMEA.

MAT also has a chimeric gamma-1 antiferritin monoclonal antibody which, when coupled to Yttrium-90, could also be used to treat pancreatic and liver cancers.

→ 6 PATENTS → 9 SALARIED STAFF



MilleGen

CEO \ Hakim KHARRAT

Contact details \ Immeuble BIOSTEP - Bât.A - Rue Pierre et Marie Curie - BP 38183 - F-31681 Labege Cedex
Tel \ +33 5 61 28 70 10
E-mail \ contact@millegen.com
Web site \ www.millegen.com
Date of founding \ Oct. 1999

FIELD OF ACTIVITY

\ Selection (from human libraries) and engineering of human, murine and other monoclonal antibodies
\ sequencing, peptide synthesis and immunization services.

KEYWORDS

\ Antibody libraries \ Library screening \ Antibody affinity improvement \ DNA sequencing \ Peptide synthesis.

DESCRIPTION

Background

MilleGen was created in 1999 by Dr Hakim Kharrat and Dr Khalil Bouayadi. It was a prizewinner in the French Ministry of Research's business plan competition for innovative companies in 1999 (in the «emerging projects» category) and 2000 (in the «creation and development» category). The company then expanded by offering DNA sequencing and peptide synthesis services, in order to finance its in-house R&D activity in the field of directed molecular evolution and recombinant human antibodies.

Description of the products/services/technology

- R&D on recombinant human antibodies for therapeutic and diagnostic purposes: a random mutagenesis technology (MutaGen™) for the improvement of immunological and pharmacological properties of human or non-human antibodies; MutalBank™ human recombinant antibody libraries for screening against a target of interest.
- In parallel: a broad range of custom genomics and peptide synthesis services.

Customer references/collaborations/highlights

After several years dedicated to the development of patented technologies (such as MutaGen™ for antibody improvement or the production of hyperdiverse libraries of recombinant antibodies), MilleGen has established a platform for selecting recombinant human antibodies and optimizing them for entry into preclinical development. MilleGen is working on therapeutic antibodies with public- and private-sector partners.

Collaborations sought

The antibody platform is targeted at pharmaceutical companies, biotech firms and academic research groups developing therapeutic antibodies.

→ **ANNUAL TURNOVER: €1.5 MILLION** → **5 PATENTS** → **24 SALARIED STAFF**

→ **STRENGTHS:** robustly patented technologies and molecules. A highly competent team of scientists with in-depth know-how in the field of recombinant antibodies and directed evolution.
→ **INNOVATION ASSETS:** MutaGen technology and hyperdiverse antibody banks.

NanoBH

CEO\ Bertrand du HALGOUET

Contact details \ 41, rue Vital - F-75116 Paris
Tel \ +33 6 11 62 43 14
E-mail \ bertrand.duhalgouet@free.fr
Date of founding \ 2007

FIELD OF ACTIVITY

\ Development of nanoparticle fabrication techniques for the encapsulation of active substances (without the need for solvent or detergents), in order to reduce adverse effects and improve the performance of active compounds.

KEYWORDS

\ Green technology \ Spontaneous assembly in water \ Cyclodextrin \ Inclusion complex / Improving the performance of active compounds.

ENTERPRISES

DESCRIPTION

Background

The company was created in order to develop and exploit two patents generated by the UMR-CNRS 8612 Physical Chemistry, Pharmaceutical Techniques and Biopharmacy Laboratory, headed by Patrick Couvreur.

Description of the products/services/technology

The technology is proven to:

- 1) reduce the unpleasant odors or tastes of certain natural products.

- 2) prolong the effect of very volatile compounds (e.g. fragrances and anti-mosquito products) by limiting evaporation.

- 3) increase the protection afforded by certain sunscreens.

The technology's applications encompass cosmetics and OTC & prescription pharmaceuticals. This new nanoparticle fabrication technique results from the spontaneous assembly in water of a beta-cyclodextrin polymer and an active compound. It enables the encapsulation of various lipophilic molecules and those forming inclusion complexes with cyclodextrins. The molar mass of the encapsulated compound can vary from 200 to about 2000.

Customer references/collaborations/highlights

Various collaborations are underway with multinational cosmetics and dermatology companies.

Collaborations sought

Cosmetics and dermatology companies.

→ 2 PATENTS → 2 SALARIED STAFF

→ **STRENGTHS:** high-performance, green technology.
→ **INNOVATION ASSETS:** environmentally friendly.

Nokad

President, Chief Executive Officer \ Amine M. ABINA
Vice-president \ François ERARD

Contact details \ Pépinière Genopole® Enterprises
4, rue Pierre Fontaine - F-91058 EVRY Cedex
Tel \ +33 1 60 87 89 90
E-mail \ contact@nokad-technology.com
Web site \ www.nokad-technology.com
Date of founding \ 21st Jan. 2004

FIELD OF ACTIVITY

\ Validation of *in vivo* targets \ Innovative therapeutics for different types of cancer \ Therapeutic vaccines.

KEYWORDS

\ Functional protein knock-out (KO) \ Therapeutic vaccines \ Treatment of thrombopenia \ Bioinformatics platform \ Rapid validation of *in vivo* targets in various species.

DESCRIPTION

Background

Nokad was founded in 2004 with the objective of developing an innovative technology platform for the *in vivo* validation of drug targets. This development work prompted Nokad to explore a newly discovered biological pathway in hematopoiesis and, in parallel, validate its vaccine approach in several in-house and external collaborative programs.

Description of the products/services/technology

Our *in vivo* target validation platform can be combined with *in silico* studies as part of a variety of experimental strategies:
- functional protein KO in various mammalian species.
- *in vivo* validation of hepatic or local targets via RNAi or shRNA delivered by a recombinant virus.
- *in vivo* overexpression of target genes using recombinant adenoviruses or adeno-associated viruses.
- antibody generation

Customer references/collaborations/highlights

- Creation of the first viable EPO-KO models in several animal species.
- Discovery of a new biological pathway in hematopoiesis, in collaboration with the INSERM.
- Launch of collaborative *in vivo* validation programs with a number of pharmaceutical and biotech companies.
- Receipt of a major grant from the French National Research Agency in 2009.

Collaborations sought

The company is seeking partners involved in the treatment of thrombocytopenia and the development of therapeutic vaccines. Nokad is also looking for a partner to distribute some of the animal models that it has developed in-house.

→ 5 PATENTS → 6 SALARIED STAFF

→ **STRENGTHS:** an innovative strategy for target validation and for vaccination. Rapidly available, high-quality information on validation.
→ **INNOVATION ASSETS:** an integrated platform for *in vivo* target validation; a novel vaccine strategy.

Novacyt

FIELD OF ACTIVITY

\ NOVACYT develops innovative medical cytology solutions (notably an entirely automated, liquid-based cytology system) which are sold worldwide.

KEYWORDS

\ *In vitro* diagnostics \ Automation
\ Liquid-based cytology.

CEO \ Éric PELTIER
Commercial Director \ GÉRALD ULRICH
Operations Director \ JEAN PIERRE CRINELLI

Contact details \ Immeuble le NUNGESSER - 13, Avenue Morane Saulnier - F-78140 VELIZY VILLACOUBLAY
Tel \ +33 1 39 46 51 04
E-mail \ info@novacyt.com - gerald.ulrich@novacyt.com
Web site \ www.novacyt.com
Date of founding \ 11th July 2006

DESCRIPTION

Background

NOVACYT was founded with the goal of becoming a major player in cytology diagnostics. The company's expertise know-how is based on its knowledge of medical cytology and the development, industrialization and commercialization of *in vitro* diagnostic devices.

Description of the products/services/technology

NOVACYT commercializes a complete thin-film cytology range. The NOVAPREP® Vial Test Gyn and Non Gyn consumables and the NOVAPREP® Decantation System are dedicated for use with the NOVAPREP® NPS25 and NPS50 processing systems.

NOVACYT sells its automated cytology solutions in France and has a worldwide distribution network.

Customer references/collaborations/highlights

In just two years, NOVACYT has developed and commercialized a fully automated solution for liquid-based cytology, which has already been adopted in over 15 countries. Thanks to its standardization and high quality, this innovative system is improving diagnostic performance levels in medical cytology.

Collaborations sought

NOVACYT is looking for commercial partners in the United States and Japan.

→ ANNUAL TURNOVER: €500 K → 15 PATENTS → 8 SALARIED STAFF

→ **STRENGTHS:** innovation, industrial processes, marketing & sales, regulatory issues. Market knowledge, product-market matching and a multidisciplinary team.

Novagali Pharma

President of the board \ Jérôme Martinez

Contact details \ 1, rue Pierre Fontaine - Genavenir 4 - F-91058 Evry Cedex
Tel \ +33 1 69 87 40 20 - Fax \ +33 1 69 87 40 33
E-mail \ contact@novagali.com
Web site \ www.novagali.com
Date of founding \ 8th Aug. 2000

FIELD OF ACTIVITY

\ Novagali Pharma is a French pharmaceutical company specializing in ophthalmology. It develops and commercializes innovative ophthalmic products for all segments of the eye, in order to help ophthalmologists improve their patients' quality of life.

KEYWORDS

\ Ophthalmology \ Cationic emulsions \ Cationorm®.

DESCRIPTION

Background

Novagali Pharma was created in August 2000 by Simon Benita. The company then set up its labs and corporate offices at the Evry Genopole®. In 2003, the company started to focus on ophthalmology and launched its first product in France in 2008.

Description of the products/services/technology

Cationorm® (Novagali's first product) was developed to treat the symptoms of dry eye syndrome, a very invalidating pathology that affects millions of people. Based on its two patented technology platforms, Novagali has developed a portfolio of diversified products in late-stage development, including Cyclokat® (a cationic cyclosporin emulsion for treating severe dry eye syndrome), Catioprost® (an innovative cationic latanoprost emulsion for treating glaucoma) and Cortiject® (a corticosteroid prodrug for treating macular edema in diabetics).

Customer references/collaborations/highlights

Since its incorporation, Novagali has raised a total of around €60 million in 4 rounds of fundraising.

In April 2008, Novagali launched the first product to come out of its pipeline: Cationorm®, a innovative cationic emulsion for treating the symptoms of dry eye syndrome.

→ 26 PATENTS → 45 SALARIED STAFF

→ **STRENGTHS:** Cationorm®, the first product on the market; 2 innovative technology platforms, with Novasorb® for the eye surface and the anterior segment and Eyeject® for administering drugs to the back of the eye. A pilot production unit for industrial-scale transfers. Novagali's staff combine experience in and knowledge of formulation, analysis, preclinical testing, manufacturing, clinical trials, regulatory affairs and marketing.
→ **INNOVATION ASSETS:** development of innovative drugs for all segments of the eye. A cationic emulsion which increase the ocular bioavailability of active substances.

ObeTherapy Biotechnology

ObeTherapy BIOTECHNOLOGY

FIELD OF ACTIVITY

\ Drug discovery for the treatment of obesity and metabolic diseases.

KEYWORDS

\ Obesity \ Type II diabetes \ Lean phenotype.

CEO \ Itzik HAROSH

Contact details \ Pépinière Genopole® Enterprises
4, rue Pierre Fontaine - F-91000 EVRY Cedex
Tel \ +33 1 60 87 89 04
E-mail \ iharosh@obetherapy.com
Web site \ www.obetherapy.com
Date of founding \ 19th Jan. 2000

DESCRIPTION

Background

ObeTherapy Biotechnology's business is based on its innovative approach to identifying novel genes that can be used as therapeutic targets in obesity. The paradigm is diametrically opposed to conventional ethos in this field: instead of looking at what genetically characterizes the obese phenotype, ObeTherapy Biotechnology is focusing on the lean phenotype.

Description of the products/services/technology

ObeTherapy Biotechnology's main goals are to:
- identify new target genes for the treatment of obesity and related pathologies.
- validate these targets by establishing transgenic animal models.
- identify new chemical entities which can modulate the products of these target genes.
- develop these NCEs up to the preclinical phase.

This has enabled it to identify, validate and patent a family of genes involved in energy supply. These genes are high potential therapeutic targets, since they are non-redundant and are very specific. Drugs that bind to these targets are identified by using a high-throughput screening method patented by ObeTherapy.

Customer references/collaborations/highlights

The discovery of new therapeutic molecules and their development up to market launch are performed in close collaboration with the Zambon group (Milan, Italy). In parallel, a new gene candidate and inhibitors have also been recently identified. The establishment of an alliance for this second target is currently under discussion.

Collaborations sought

ObeTherapy Biotechnology is currently seeking industrial and financial alliances, in order to finalize the preclinical trials on two lead targets.

→ 5 PATENTS → 2 SALARIED STAFF

→ **STRENGTHS:** one molecule in the preclinical phase and another in lead optimization.
→ **INNOVATION ASSETS:** ObeTherapy looks at targets produced in a lean phenotype.



Oxalya

CEO \ Alban SCHMUTZ

Contact details \ 18-20, rue Pasteur
F-94270 Le Kremlin Bicêtre
Tel \ +33 820 48 44 40 - Fax \ +33 1 45 59 02 51
E-mail \ info@oxalya.com
Web site \ www.oxalya.com
Date of founding \ May 2003

FIELD OF ACTIVITY

\ Oxalya provides a comprehensive range of scientific calculation and numerical simulation software and services for public- and private-sector R&D centers. The company is structured into 3 divisions: Infrastructure, Software and HPC On Demand

KEYWORDS

\ High-performance calculation (HPC) \ Numerical simulation \ HPC on demand \ Software house \ Solution deployment.

Background

Since 2003, Oxalya's staff have developed in-depth know-how in the field of high-performance calculation and numerical simulation. This expertise enables the company to offer a specifically market-matched set of hardware and software technologies.

Description of the products/services/technology

Oxalya offers the *Virtual Nodes*© remote HPC service with secure web access and guaranteed cluster booking within 24 hours.
Oxalya also sells software:
- Hurricane©: HPC cluster management software
- VisuaPortal©: On-demand remote visualization resource management software for businesses
- ComputePortal©: A multi-site and multi-scheduler submission manager

Customer references/collaborations/highlights

Oxalya also contributes to several major R&D projects - enabling researchers and engineers to focus on their research via the use of collaborative, easy-access, interoperable solutions.

Oxalya leads the SCOS consortium (www.oscos.org, which proposes interoperability standards for scientific calculation applications) and is also a member of the CARRIOCAS project (www.carriocas.org) aimed at developing infrastructure for remote collaboration between scientists (data visualization & treatment, collaboration, etc.).

PartnerChip

FIELD OF ACTIVITY

\ PartnerChip offers its customers a panel of tools for genomics, high-density microarray analysis, diagnostics and bioinformatics.

KEYWORDS

\ Biomedicine \ Microarray \ Diagnostics \ Genomics \ Bioinformatics.

CEO \ Pascal SOULARUE

Contact details \ Bâtiment G2 - 2, rue Gaston Crémieux
F-91000 EVRY
Tel \ +33 1 60 87 34 62
E-mail \ pascal.soularue@partnerchip.fr
pascal.soularue@cea.fr
Web site \ www.partnerchip.fr
Date of founding \ 25th Jan. 2005

DESCRIPTION

Background

PartnerChip was incorporated in January 2005 and is an accredited Affymetrix Official Service Provider. Since 2007, PartnerChip has been developing its own diagnostic microarrays. In December 2008, PartnerChip became an official European supplier for Perkin-Elmer molecular diagnostics.

Description of the products/services/technology

PartnerChip offers services such as array design, spotting quality control, targeted on-chip hybridization on chips (gene expression, exon jumping analysis, genotyping, resequencing, comparative genomic hybridization, microRNAs, etc.), array preparation and reading, generation and analysis of raw data (normalization, comparison, statistical analysis, clustering, pathway involvement and data mining).

PartnerChip also develops resequencing chips for diagnostics and protein chips.

Customer references/collaborations/highlights

PartnerChip is involved in the Medicen Paris Region cluster's Biotype project and in four European Union projects (EuroIron, ProteinStorage, PrediCancer and NMD-Chip).

Collaborations sought

PartnerChip is seeking to establish collaborations with all types of biotech firms (red, green and white), pharmaceutical companies and CROs.

→ **ANNUAL TURNOVER:** €230 K → **6 SALARIED STAFF**

→ **STRENGTHS:** responsiveness, creativity, 18 years of experience in genomics.
→ **INNOVATION ASSETS:** the development of new tools in the field of diagnostics.

Phenopups

Heads of project \ Estelle DURAND
Boris MATROT
Expert \ Jorge GALLEGO (DR Inserm)

**Contact details ** Phenopups - Inserm U676 -
Hôpital Robert Debré - 48, Bd Sérurier - F-75019 Paris
**Tel ** +33 1 40 03 19 91
**E-mail ** contact@phenopups.com
**Web site ** www.phenopups.com
**Date of founding ** 2009

FIELD OF ACTIVITY

\ Service company for *in vivo* phenotyping of new-born and juvenile rodents, applied to safety and efficacy testing of pediatric drugs.

KEYWORDS

\ Pediatric drugs \ Non-invasive \ Phenotyping \ Preclinical \ Rodents.

ENTERPRISES

DESCRIPTION

Background

By interfacing with clinicians at Debré Medical Center (Paris) and INSERM researchers in developmental biology, Phenopups' engineers have developed new technological tools. The objective is to better adapt drug treatments to pediatric use.

Description of the products/services/technology

We have developed a rodent *in vivo* phenotyping platform for the non-invasive investigation of physiological (cardiorespiratory) functions, cognitive processes and development from birth up to weaning. This has generated two applications:
- a diagnostic service for rodent models of pediatric diseases.
- a service for preclinical development of pediatric drugs.

Customer references/collaborations/highlights

Phenopups is the only technology platform to offer an innovative phenotyping service for genetically modified mouse pups. Trophos was our first customer for this service offering in 2008. Our pediatric drug testing service is now being validated as part of the European Union FP7 TINN project.

Collaborations sought

We are looking for partners in the field of pediatric drug development, with a view to building European, national or regional projects.

→ 1 PATENT

→ **STRENGTHS:** an innovative functional investigation platform for the non-invasive, rapid and reproducible monitoring of very small rodents (a few cm in length).
→ **INNOVATION ASSETS:** preclinical studies of models that are more predictive for the development of pediatric drugs.

Phinc Development

PhinC Development

FIELD OF ACTIVITY

\ Methodological and scientific project support for biotech firms and small labs for preclinical development and Phase I and IIa clinical development.

KEYWORDS

\ Early-stage development (preclinicals, Phase I & IIa clinical trials) \ Analysis of exploratory data and PK and PD results \ Pharmacometrics.

CEO\Co-founders \ Bernard ORLANDINI, Virginie GUALANO, Mathieu FELICES

Contact details \ 5, rue Henri Desbruères - Immeuble Genavenir 8 - F-91030 Evry Cedex
Tel \ +33 1 60 87 14 79 - Fax \ +33 1 60 87 14 75
E-mail \ bernard.orlandini@phinc.fr
Web site \ www.phinc.fr
Date of founding \ 23/10/2008

ENTERPRISES

DESCRIPTION

Background

PhInC was incorporated by 3 experienced CRO/ pharmaceutical professionals with complementary skills (pharmacology, biostatistics, pharmacokinetics, biomedical research and clinical development).

Description of the products/services/technology

Based on a integrated approach and the multi-disciplinary provision of operational support for clinical research in biotech or small pharma companies (without taking over the project), PhInC intervenes in three areas:
1/ - scientific and methodological advice, from the preclinical phases through to first-in-man trials and proof-of-concept in the patient. As a natural extension of this approach, PhInC can evaluate the corresponding resources and operational costs (partners, investments, infrastructure, timelines, etc.).
2/ - trial design and coordination of study set-up and execution. This step also includes constitution of a body of related regulatory and scientific documentation, as well as selection and monitoring of the most appropriate subcontractors (CROs and academic labs).
3/ - expert opinion and exploratory analyses in order to deepen the regulatory development and leverage investigational product potential from Phase IIa onwards. There are many different examples (validation of target activity, determination of the therapeutic dose, exploration of exposure/ response relationships, possible correlations or potentiation possible, point-of-care techniques) and methodologies used (PK and PD analyses, PK/PD modeling, population analyses, meta-analyses, etc.).

These approaches are based on the integration of custom skills from various disciplines related to biopharmaceutical development.

Customer references/collaborations/highlights

PhInC works online with more than 10 biotech companies and small pharma companies at various stages of product development. Furthermore, a framework agreement on the performance of exploratory analyses has been signed with two of the big five pharma companies.

Collaborations sought

Exploratory analyses with biotech firms, small pharma companies and multinationals. Co-development of new methods and novel protocols in the field of clinical development.

→ 7 SALARIED STAFF

→ **STRENGTHS: -** optimization of early-phase development costs and timelines by applying an upstream, made-to-measure approach for small pharma companies - enabling them to keep control of their development and independence when faced with the large CROs.



Physikron

CEO \ **Patrick VAYN**
CSO \ **David SCIGOCKI**

Contact details \ Pépinière Genopole® Enterprises
4, rue Pierre Fontaine - F-91058 Evry Cedex
Tel \ +33 1 60 87 89 87 - Fax \ +33 1 60 87 89 99
E-mail \ patrick.vayn@physikron.com
Web site \ www.physikron.com
Date of founding \ 22nd June 2005

FIELD OF ACTIVITY

\ Development of new mass spectrometry solutions.

KEYWORDS

\ Tandem mass spectrometry \ High-throughput \ Low sample requirement.

ENTERPRISES

DESCRIPTION

Background

Physikron has developed analytical processes for tandem mass spectrometry (MS-MS) based on concepts from particle physics.

Description of the products/services/technology

These processes simultaneously produce several well-separated MS-MS spectra (with no selection of the individual primary mass) from a single MS-MS spectrum containing all the fragments of several different primary masses.

Machines equipped with the Physikron system can significantly increase their acquisition throughput and decrease their sample requirement in MS-MS mode.

A higher acquisition throughput is particularly significant for liquid chromatography-coupled systems (LC MS-MS) because existing machines are only able to produce a part of the MS-MS spectra for the different primary masses going through the chromatography line. The system has notable uses in proteomics, medical diagnostics, and supramolecular chemistry.

Customer references/collaborations/highlights

Collaboration with an academic lab. Proof-of-concept has been achieved.

Collaborations sought

Physikron is looking for co-development and/or licensing partners (mass spectrometers manufacturers, the players in medical diagnostics, safety and environment.

→ 3 PATENTS → 1 SALARIED STAFF

→ **STRENGTHS:** rapidity, analysis of complex mixtures and sample consumption strongly reduced.

Sanofi-Aventis
Evry Genetics Center

FIELD OF ACTIVITY

\ Sanofi Aventis' ambition is to become a diversified healthcare company, focused of patients' needs. Its strategy is based on:
• innovation in R&D
• modulation of its corporate organization to meet the challenges to come
• external growth opportunities.

KEYWORDS

\ Human genetics \ Epigenetics
\ Pharmacogenetics.

Director \ Jean-François DELEUZE

**Contact details ** 2, rue Gaston Crémieux - CP 5705
91057 EVRY Cedex
**Tel ** +33 1 60 79 87 00
**E-mail ** nathalie.garrabos@sanofi-aventis.com
**Web site ** www.sanofi-aventis.com
**Date of founding ** Jan. 1998

Background

Sanofi Aventis' worldwide center for human genetics is linked to the Vitry-Alfortville-Evry Research Center for upstream research and preclinical development. The Human Genetics Center's goal is to better understand the causes and mechanisms of disease. It currently has around 40 staff.

Description of the products/services/technology

- identification, annotation and validation of targets, applied to sanofi-aventis' various disease areas.

- development of screening tests.

- discovery of genetic markers of interest for clinical development (pharmacogenetics).

- genetic support for research programs.

→ ANNUAL TURNOVER: €27.6 BILLION → MORE THAN 100,000 STAFF IN OVER 100 COUNTRIES

→ **STRENGTHS:** the global leader in vaccines. A good balance between traditional and emerging markets.
→ **INNOVATION ASSETS:** a large portfolio of pharmaceuticals, with prescription drugs, generics and OTC products.



Sebia

CEO \ Benoît ADELUS

Contact details \ Parc Technologique Léonard de Vinci
CP 8010 Lisses - F-91008 EVRY Cedex
Tel \ +33 1 69 89 80 80
E-mail \ sebia@sebia.com
Web site \ www.sebia.com
Date of founding \ Oct. 1967

FIELD OF ACTIVITY

\ Design, production and commercialization of *in vitro* diagnostic systems (instruments and reagents) for medical biology laboratories.

KEYWORDS

\ *In vitro* diagnostics \ Clinical biochemistry \ Electrophoresis \ Instruments / Reagents \ Monoclonal gammopathies.

ENTERPRISES

DESCRIPTION

Background

Since its incorporation forty years ago, SEBIA has become a global leader of innovative electrophoretic *in vitro* diagnostic systems and particular in capillary electrophoresis.

Description of the products/services/technology

Electrophoresis consists in the use of an electrical field to separate the proteins contained in biological samples. The most recent capillary electrophoresis techniques is applied in the dedicated CAPILLARYS and MINICAP automated systems (launched in 2007). The HYDRASYS range (with more automation in version 2), utilizes an agarose gel technique and is a leading technology in the diagnosis of immune system diseases, myeloma and hemoglobin abnormalities and the detection of other protein markers.

Customer references/collaborations/highlights

SEBIA's R&D efforts are delivering results in two fields:
- the development of semi-automated or fully automated high-throughput systems, plus a full range of applications: proteins, lipoproteins, hemoglobin, etc. SEBIA recently acquired and integrated Beckman Coulter Inc's electrophoresis business.
- via its 8 subsidiaries and a network of 80 distributors, SEBIA offers a incomparable level of service worldwide.

Collaborations sought

SEBIA maintains close links with the medical community, including university labs associated with its research work and disease specialists developing applications. pour lesquelles sont développés des applicatifs.

→ ANNUAL TURNOVER: €100 MILLION → 370 SALARIED STAFF

→ **STRENGTHS:** the world number 1 in electrophoresis technology – strong innovation capacity - a leader in the diagnosis of monoclonal gammopathies - high-level scientific and technical support.
SEBIA: Energy to advance, the force to innovate.

Serial Genetics

serialgenetics
innovations in molecular diagnostics

FIELD OF ACTIVITY

\ Serial Genetics designs, develops and commercializes innovative molecular diagnostics kits for medical labs and industry.

KEYWORDS

\ Molecular diagnostics \ CE-IVD
\ Hereditary diseases \ Pharmacogenetics
\ Development of diagnostic kits.

Director \ Christophe VALAT

Contact details \ Genopole® Campus 1
5, rue Henri Desbruères - F-91030 EVRY Cedex
Tel \ +33 1 60 77 45 16
E-mail \ cvalat@serialgenetics.com
Web site \ www.serialgenetics.com
Date of founding \ 3rd Nov. 2003

DESCRIPTION

Background

Since its incorporation in 2003, Serial Genetics has developed a range of CE-marked IVD molecular diagnostic products for hereditary diseases and speciation. The company is moving towards pharmacogenetics and microbiology kits.

Description of the products/services/technology

Serial Genetics' kits are based on its proprietary HairLoop™ probe technology, enabling the simple, rapid analysis of all types of mutations without the need to use complex instrumentation.

Serial Genetics uses this technology in its first HairLoop™ CF kit for the analysis of 49 mutations in cystic fibrosis, and is developing several other kits in-house. Custom kit development services are also available, with shorter timelines and lower costs.

Furthermore, Serial Genetics produces and commercializes the endonuclease ENDO-1 for mutation discovery and TILLING® in medical and plant genomics research (licensed from INRA/ Genoplante).

Customer references/collaborations/highlights

Serial Genetics collaborates with pharmaceutical & biotech companies and academic labs in France and abroad.

Collaborations sought

The company is seeking collaborations on biochip production and product distribution in Europe and the USA.

→ 4 PATENTS → 5 SALARIED STAFF

→ **STRENGTHS:** ability to rapidly develop CE-marked IVD kits.
→ **INNOVATION ASSETS:** consolidation of the competitors' various molecular diagnostics products into a single kit.

Sigma-Aldrich France

Director \ **Philippe DURIVAL**
Operations manager Evry \ **Jean CHABBERT**

Contact details \ Genopole Campus 1
5, Rue Henri Desbruères - F-91030 EVRY
Tel \ +33 1 60 87 59 00 - Fax \ +33 1 60 87 59 09
E-mail \ jean.chabbert@sial.com
Web site \ www.sigma-aldrich.com
Date of founding \ 8th March 2002

FIELD OF ACTIVITY

\ Sigma-Aldrich develops, produces and commercializes chemical and biochemical reagents for scientific research and analysis, R&D and production. The Sigma-Aldrich site in Evry specializes in the custom synthesis of oligonucleotides intended for genomics, pharmaceutical research and the diagnostics industry.

KEYWORDS

\ Oligonucleotides \ Primers \ SiRNA \ Probes \ qPCR.

DESCRIPTION

Background

Oligonucleotide production started on Sigma Aldrich France's Evry site in 2005, following the acquisition of Proligo. For nearly 20 years, Sigma Aldrich's international oligonucleotide business has grown steadily and the company now has 10 strategically located production sites worldwide (USA, Canada, Singapore, Australia, Japan, etc.).

Description of the products/services/technology

Thanks to its production and R&D site in Evry, Sigma Aldrich is able to offer researchers (in France and worldwide) high-quality oligonucleotides with very short timelines, thanks to its high-throughput automated synthesis platform. Sigma Aldrich's acknowledged know-how in the synthesis of DNA, siRNA, quantitative PCR probes and modified oligonucleotides means that the company can provide optimal solutions for genomics, pharmaceutical research and diagnostics.

Customer references/collaborations/highlights

Sigma Aldrich France's R&D teams have been involved in more than 50 scientific collaborations over the last three years. More than 20 scientific articles have been published and several patent applications have been filed as a result of these collaborations. The acquisition of strategic licenses (such as that from MIT, related to the production of siRNA) has enabled Sigma Aldrich France to position itself in the biotech field and thus complement Sigma Aldrich's general product range.

Collaborations sought

Sigma Aldrich France is developing collaborations in genomics, functional genomics and all related applications. In 2008, the company made several investments in medium-scale (mg) production of oligonucleotide, in order to broaden out the product range into the diagnostics sector.

→ 6 PATENTS → 50 SALARIED STAFF

→ **STRENGTHS:** a large range of high-quality products and services. Technology, expertise and innovation.
→ **INNOVATION ASSETS:** custom development of new products and solutions.



Sinovia

SINOVIA

FIELD OF ACTIVITY
\ Industry computer networks.

KEYWORDS
\ Industrial IT networks.

CEO \ Carlos MORENO

Contact details \ 3, rue de Chevilly - F-94260 FRESNES
Tel \ +33 1 49 84 60 00
E-mail \ infos@sinovia.com
Web site \ www.sinovia.com
Date of founding \ 21st Apr. 1998

ENTERPRISES

DESCRIPTION

Background

For the last ten years, SINOVIA has been designing innovative technologies for infrastructure supervision.

Description of the products/services/technology

Our clients have chosen SINOVIA in order to benefit from a unique, powerful solution which federates multi-technique, multi-service, multi-manufacturer facilities.

SINOVIA's solutions not only ensure optimal management of potential threats (natural disasters, malevolent acts, etc.) but also enable centralized, intelligent supervision of cities, sites or buildings.

SINOVIA has the following product offerings: CCTV networks, intelligent city/street lighting management systems, infrastructure supervision and monitoring (intrusion detection, fire safety, alarm control, energy consumption, etc.), mass notification alerts, and infrastructure/equipment interoperability.

Collaborations sought

SINOVIA's approach perfectly addresses the expectations and requirements of public- and private-sector organization in terms of system security, sustainable development, cost optimization and resource sharing.

Sphergen

Manager \ Yves SCHERMAN

Contact details \ Pépinière Genopole® Enterprises
4, rue Pierre Fontaine - F-91058 EVRY Cedex
Tel \ +33 1 49 58 95 50
Date of founding \ 1st Jul. 2004

FIELD OF ACTIVITY

\ Sphergen is elaborating an innovative process for non-viral gene transfer called «electrotransfer»; this enables the delivery of veterinary drugs for the treatment of currently incurable diseases.

KEYWORDS

\ Non-viral gene therapy
\ Delivery of active compounds.

DESCRIPTION

Background

he technology is derived from work performed by Yves Scherman, the company's founder and manager.

Description of the products/services/technology

Sphergen's technology could be used for target validation purposes and the development of biomolecules by R&D departments in major pharmaceutical companies.

Customer references/collaborations/highlights

In addition, Sphergen collaborates to proof-of-concepts studies concerning the production by genetic immunization of antisera with antitoxin or antiviral activity for passive immunization therapy.

Collaborations sought

R&D collaborations (delivery, anti-serum development, target validation, etc.) with academic or industrial pharma/biotech partners.

→ **STRENGTHS:** a proprietary electrotransfer platform.

Statlife

FIELD OF ACTIVITY

\ Statlife develops software for quantified evaluation of the benefits and risks associated with changes in drug regimens or in behavior (food habits, smoking, etc.), with a view to better prevention of today's major diseases.

KEYWORDS

\ Prevention \ Prediction \ Patient medical records \ Risk scores \ Epidemiological statistics.

CEO \ Stéphane RAGUSA

Contact details \ Bâtiment Maurice Tubiana
Institut Gustave Roussy - 39, rue Camille Desmoulins
F-94805 Villejuif Cedex
Tel \ +33 1 45 67 20 47
E-mail \ ragusa@statlife.fr
Web site \ www.statlife.fr
Date of founding \ 22nd Apr. 2004

DESCRIPTION

Background

Statlife was spun out from research work on disease risk prediction carried out at the Pierre & Marie Curie University of Paris and INSERM. The company mines epidemiological data from the INSERM's prospective cohorts.

Description of the products/services/technology

Statlife's various products and services are provided (i) by health insurers to their members, (ii) by companies to their employees or (iii) directly to pharmaceutical companies.
Statlife notably develops medical software packages for risk evaluation in diseases that depend on behavioral parameters (food habits, smoking, etc.), biological parameters and the administration of drug treatments. This personalized evaluation enables a better-informed therapeutic choice by the patient and his/her physician. Statlife also develops tools for nutritional prevention and the identification of nutritional deficits, with suggestions for possible modifications.

Customer references/collaborations/highlights

Statlife collaborates with several international pharmaceutical laboratories as part of Phase IV clinical trials to improve the prescription criteria for several marketed drugs. The company has notably developed a software package for justifying the prescription of hormone substitution treatments (delimitation of the population to be screened as part of preventive treatment) by quantifying a woman's risk of breast/ovary/endometrial cancer and osteoporosis.

Collaborations sought

Statlife wishes to offer its expertise to pharmaceutical companies keen to better qualify their drugs' target populations.

→ ANNUAL TURNOVER: €200 K → 2 PATENTS → 4 SALARIED STAFF

→ **STRENGTHS:** collaborations involving large, prospective cohorts. The potential to optimize drug prescription criteria during the registration or post-marketing phases.

Tech Innovation

Manager \ Vincent ARTIGUE

Contact details \ **Headquarters:** 15, rue mademoiselle
F-91140 Villebon sur Yvette
Office: 40 rue du Pelvoux - F-91020 Evry Courcouronnes
Tel \ +33 1 69 47 75 88
E-mail \ info@techinnovation.fr
Web site \ www.techinnovation.fr
Date of founding \ 2nd June 2000

FIELD OF ACTIVITY

\ Design and development of innovative products in the field of arm prostheses.

KEYWORDS

\ Orthopedics \ Prostheses
\ Myoelectric devices \ Arms.

Background

TechInnovation was created in order to help people who are unable to use one or both arms normally. Previous, in-depth experience in robotics has enabled the company founders to design novel products.

Description of the products/services/technology

The company's first challenges involved designing a myoelectric prosthesis for the elbow and then for the hand, as well as a new generation of myoelectric sensors. TechInnovation addresses even the apparently simplest problems, such as an assistive device for helping arthritis suffers to open a bottle.

Customer references/collaborations/highlights

Collaboration with AFM, THALES, CEA, LISV and the Raymond Poincaré Hospital (Garches) in the study and design of an orthosis for people with muscular dystrophy. This device must enable the person to use his/her arm normally again.

Collaborations sought

Financial partners, as well as distributors to market our various products. Technical collaborations to develop new products.

→ **ANNUAL TURNOVER: €300 K** → **4 PATENTS** → **4 SALARIED STAFF**

→ **STRENGTHS:** dynamism, responsiveness. Understanding and analysis of the issues.

Texcell

FIELD OF ACTIVITY

\ Texcell offers fully GLP- and GMP-compliant viral safety testing and immunomonitoring services.

KEYWORDS

\ Viral safety testing \ Viral and prion validation \ Immunomonitoring \ Immunoprofiling \ Healthcare.

CEO \ Bernard PLICHON

Contact details \ Genavenir 1 & 5
1, rue Pierre Fontaine - F-91058 EVRY Cedex
Tel \ +33 1 60 91 33 10 - Fax \ +33 1 64 93 33 24
E-mail \ info@texcell.fr
Web site \ www.texcell.fr
Date of founding \ 28th Jan. 2003

DESCRIPTION

Background

Texcell is a service company offering GLP- and GMP-compliant viral safety testing and immunology services. Thanks to over 20 years' experience in the performance of biosafety and viral validation tests, we have evaluated a large number of products - including some that have received marketing approval from the FDA, the EMEA and the MHW. Our expertise is acknowledged worldwide and (since 2006) we have developed commercial relationships with representatives based in Japan, India and South Korea. In 2008, we created a US subsidiary (Texcell Inc.), in order to strengthen our presence on the American continent.

Description of the products/services/technology

Texcell offers a full catalogue of assays for the characterization of cell banks, the batch release of cell-derived biotechnological products and viral validation studies for evaluating the ability of industrial process steps to eliminate and/or inactivate viruses (over 30 relevant or model viruses are available) and prions.

Texcell acts as both a contract research organization and a central lab for preclinical and clinical trials. We offer an immunology-dedicated technology platform with an exhaustive range of GLP assay development services (optimization and validation) for analyzing the immune response to humoral and/or cell-based mediation.

Today's compound development timelines have to be as short as possible. Viral safety testing, viral validation studies and clinical studies must be continually improved, in order to optimize your therapeutic strategy. We act as a true partner for our customers and commit out staff to offering you the right experimental protocols and tools for your projects.

→ 45 SALARIED STAFF

→ **STRENGTHS:** an international service company that is responsive and has a close relationship with its customers. Expertise in virology and immunology.
→ **INNOVATION ASSETS:** a specialist in viral and prion safety.
→ **OTHER FACTS:** as an expert provider in virology, Texcell evaluates the viral safety of recombinant proteins, monoclonal antibodies, medical devices and other products of animal or human origin (such as blood-derived products, heparins, hyaluronic acid and collagens). The company also has expertise in immunomonitoring. Texcell develops and validates assay that monitor the immune response to cell-based and/or humoral mediation in clinical trials (ELISA, cytometry, neutralizing serums, hemagglutination inhibition assays, bioassays, Luminex).

Theraclion SAS

President/CSO \ **Francois LACOSTE**
CEO \ **Ismael NUJURALLY**

Contact details \ Paris Santé Cochin
29, rue du Faubourg Saint Jacques - F-75014 Paris
Tel \ +33 1 53 10 30 90
E-mail \ contact@theraclion.fr
Web site \ www.theraclion.fr
Date of founding \ 5th Aug. 2004

FIELD OF ACTIVITY

\ The development, manufacture and commercialization of medical devices for the non-invasive treatment of tissues with high-intensity, focused ultrasound (HIFU).

KEYWORDS

\ Ultrasound \ Parathyroid
\ Medical instrumentation \ Therapy.

DESCRIPTION

Background

August 2004: Theraclion is founded on the basis of work performed by INSERM researchers and the company EDAP.
April 2005: Truffle Venture becomes a shareholder, enabling continuation of Theraclion's technical and clinical development.

Description of the products/services/technology

Thyros is a HIFU-based system for the non-invasive, ambulatory treatment of tissues. It is used to treat certain disease conditions of the neck (notably thyroid nodules and the hyperparathyroidism).

Customer references/collaborations/highlights

- November 2007: Thyros obtains the CE mark.
- December 2008: OSEO awards an €8.5 million grant-in-aid.

Collaborations sought

Industrial partners.

→ 19 PATENT FAMILIES → 9 SALARIED STAFF

→ **STRENGTHS:** innovative, well-characterized technology. A significant market with unmet needs in the treatment of hyperparathyroidism; a strong financial partner.
→ **INNOVATION ASSETS:** non-invasive tissue treatment.

Vaxon Biotech

FIELD OF ACTIVITY

\ A biopharmaceutical company developing innovative cancer therapeutics (notably for lung, liver, prostate, breast and colon cancer).

KEYWORDS

\ Optimized cryptic peptides \ Immunotherapy \ Vaccine \ Oncology.

Chairman \ **Pierre TEILLAC**
CEO \ **François VALLET**
CSO \ **Kostas KOSMATOPOULOS**

Contact details \ 3-5 impasse Reille - F-75014 Paris
Tel \ +33 1 45 88 67 62
E-mail \ info@vaxon-biotech.com
Web site \ www.vaxon-biotech.com
Date of founding \ 8th Jan. 2004

DESCRIPTION

Background

The company is based on an invention originally patented by Dr Kostas Kosmatopoulos and his research group at Institut Gustave Roussy/INSERM: optimized cryptic peptides, which stimulate the immune system so that it specifically destroys tumor cells.

Description of the products/services/technology

The vaccines developed by Vaxon target antigens that are over-expressed in tumor cells and hardly expressed in healthy tissues.
The company's two lead products are Vx-001 and Vx-006:
- Vx-001 has obtained orphan drug status for non-small cell lung cancer from the EMEA (in 2007) and the FDA (in 2009). It is set to enter a pivotal Phase III clinical trial in this indication.
- Vx-006 is due to start a Phase I/II clinical trial in prostate cancer patients.
- In parallel, Vaxon is developing a portfolio of cancer therapeutics for all the main HLA allotypes.

Customer references/collaborations/highlights

- With 116 patients treated to date, Vx-001 has demonstrated excellent safety, a high immune response rate (80%) and initial proof of efficacy.
- Vx-006 is currently completely its regulatory preclinical studies.

Collaborations sought

Vaxon Biotech's technology and R&D are available for strategic alliances.

→ 7 PATENTS → 4 SALARIED STAFF

→ **STRENGTHS:** a vaccine in late-stage clinical development (Phase II trials).
→ **INNOVATION ASSETS:** optimized cryptic peptides.

Viroxis

President \ **Anne-Catherine JOUANNEAU**
Chairman of the Scientific Council \
Thierry HEIDMANN

Contact details \ 11, rue Edouard Detaille - F-75017 PARIS
Tel \ +33 1 43 26 21 99
E-mail \ ac_jouanneau@noos.fr - heidmann@igr.fr
Date of founding \ 25th Nov. 2005

FIELD OF ACTIVITY

\ Viroxis designs and develops vaccines and drugs against human or animal retroviral pathogens, notably the HIV retrovirus that causes AIDS.

KEYWORDS

\ Retrovirus \ Prophylactic and therapeutic vaccines \ Antiviral compounds.

DESCRIPTION

Background

Work at the CNRS UMR8122 research unit (headed by Thierry Heidmann) at the Gustave Roussy Institute has identified retroviral protein domains that have immunosuppressant activity. Targeted mutations have been used to very significantly increase the immunogenicity of the corresponding viral proteins.

Description of the products/services/technology

On the basis of UMR8122's work, Viroxis is developing (i) antigens and optimizing vaccines for HIV and other human or animal retroviruses and (ii) drug candidates that neutralize the identified domains.

Customer references/collaborations/highlights

Viroxis' development work and future products are protected by 4 proprietary or exclusively licensed patent families.

→ 4 PATENT FAMILIES → 2 SALARIED STAFF

VitamFero SAS

FIELD OF ACTIVITY

\ Design and development of new vaccines via exploitation of a patented technology platform based on an attenuated strain of *Toxoplasma gondii*.

KEYWORDS

\ Attenuated live vaccines \ Toxoplasmosis \ Neosporosis \ Apicomplexes.

Chairman \ **Alain de la BIGNE**
CEO \ **Dr. Pascal BRETON**
R&D Director \ **Dr. Edouard SÈCHE**

Contact details \ 4, rue Pierre Fontaine
F-91058 EVRY Cedex
Tel \ +33 6 82 65 47 69
E-mail \ pbreton61@aol.com
Web site \ www.vitamfero.com
Date of founding \ 27th Oct. 2007

DESCRIPTION

Background

VitamFero was spun out of academic work performed at the UMR 483 research unit (François Rabelais University of Tours/INRA), in collaboration with the CNRS. The company's founders are committed to exploiting the Toxo KO attenuated, patented vaccine strain of *Toxoplasma gondii*.

Description of the products/services/technology

The Toxo KO attenuated strain results from the complete elimination of T. *gondii's* 2 virulence genes, it remains strongly immunogenic but lacks any pathogenic properties. These characteristics make Toxo KO and ideal tool for developing a veterinary and human vaccine against congenital toxoplasmosis. Toxo KO also serves as a gene expression vector that enables other parasitic pathogens to be targeted.

Customer references/collaborations/highlights

VitamFero was founded on the basis of its success in the French Ministry of Research's 2005 business plan competition for innovative companies. In 2008, the signature of exclusive, worldwide license agreements with François Rabelais University, the INRA and the CNRS and sub-licensing and distribution agreements with one of world leaders in the veterinary healthcare sector constituted a key milestone in the company's development.

Collaborations sought

In addition to upstream, collaborative R&D partners (with a horizon of a couple of years), VitamFero is seeking one or more licensees for commercialization of its vaccines in the human healthcare market.

→ ANNUAL TURNOVER: €150 000 → 21 PATENTS → 7 SALARIED STAFF

→ **STRENGTHS:** a technology platform which provides many opportunities for designing and developing novel live vaccines. A business model which uses the veterinary market to fund the development of vaccines for human healthcare.
→ **INNOVATION ASSETS:** a safe, effective approach which is being strongly encouraged by the EMEA
→ **OTHER FACTS:** perfectly identified and validated markets in both the veterinary and human healthcare sectors.



WatchFrog

CEO \ **Gregory LEMKINE**

Contact details \ Bâtiment GenAvenir 3
1, rue Pierre Fontaine - F-91058 Evry Cedex
Tel \ +33 1 69 36 11 15 - Fax \ + 33 6 16 39 81 91
E-mail \ info@watchfrog.fr
Web site \ www.watchfrog.fr
Date of founding \ Nov. 2005

FIELD OF ACTIVITY

\ WatchFrog sells *in vivo* biotechnological solutions (based on fluorescence emission) for evaluating the therapeutic, toxic or pollutant potential of all types of chemical or biological compounds.

KEYWORDS

\ *In vivo* \ Toxicity \ Environment \ Endocrine \ Nervous system.

DESCRIPTION

Background

WatchFrog is a service and contract testing provider for several major industrial customers, all of whom are world leaders in their respective fields: water, energy, consumer goods, fine chemicals and pharmaceuticals. WatchFrog has a routine screening platform that meets the quality standards required by its industrial customers.

Description of the products/services/technology

In the environmental sector, WatchFrog offers modular systems for the real-time monitoring of the presence of pollutants in industrial effluent.

For the environmental, chemicals and pharma sectors, WatchFrog has its own automated screening platforms (with a throughput of several hundred samples over a few hours). Moreover, WatchFrog sells routine tests for screening for the endocrine-disrupting properties of chemical compounds under the European Union's REACH legislation and Water Framework Directive.

WatchFrog can also create dedicated disease models for the pharmaceutical industry.

Customer references/collaborations/highlights

WatchFrog and the Environmental Protection Agency (USA EPA) have signed a collaboration agreement as part of the TOXCAST program for prioritizing the toxicity testing of large numbers of chemicals. WatchFrog is a member of the French National Research Program on Endocrine Disruptors (PNPRE). WatchFrog coordinates the Alternative Model for Brain Research project accredited by the Medicen Paris Region cluster; the goal is to accelerate the development of therapeutic solutions for neurodegenerative or demyelinating diseases.

Collaborations sought

In view of the flexibility of WatchFrog's technology, we are looking for new industrial partners to take up new challenges in lead optimization or environmental risk evaluation.

→ **ANNUAL TURNOVER: €500 K** → **2 PATENTS** → **10 SALARIED STAFF**

→ **STRENGTHS:** miniature, industrializable vertebrate models. A technology platform that complies with international quality standards for the production of aquatic material and molecular screening.
→ **INNOVATION ASSETS:** real-time monitoring of environmental risks on industrial sites.
→ **OTHER FACTS:** the creation of custom disease models.

Wittycell

FIELD OF ACTIVITY
\ Development of vaccine adjuvants.

KEYWORDS
\ Adjuvant \ Vaccine \ NKT cells \ Healthcare.

Chairman \ **Miguel SIELER**
CEO \ **Vincent SERRA**

Contact details \ **Main office:**
8 bis, rue du Gabriel Voisin - F-51100 REIMS
Branch office:
4, rue Pierre Fontaine - F-91058 EVRY cedex
Tel \ +33 1 60 87 89 83 - Fax \ +33 1 60 87 89 99
E-mail \ vserra@wittycell.com
Web site \ www.wittycell.com
Date of founding \ Aug. 2005

DESCRIPTION

Background
Wittycell uses a proprietary technology (inlicensed from three American institutes and based on the stimulation of NKTi cells) to develop novel vaccine adjuvants.

Description of the products/services/technology
Wittycell developed Immunomodulator adjuvants based on NKT agonist glycolipids, for therapeutic and prophylactic vaccines against infectious diseases and cancer.

Customer references/collaborations/highlights
Wittycell S.A.S has strong intellectual property position with major partnerships including the Jean Godinot Institute (France), the Institute for Medical Immunology (Belgium), the Scripps Research Institute (USA), the University of Chicago (USA) and the Brigham Young University (USA).

The first 3 immunomodulators leads are in preclinical development. (clinical batches are being manufactured).

Collaborations sought
Pharma/vaccine companies looking for novel adjuvants.

→ 14 PATENTS → 10 SALARIED STAFF

→ **STRENGTHS:** a network of international experts in biotechnology, molecular modeling, cell biology, clinical trials and virology.

XenTech

President & CSO \ Jean Gabriel JUDDE
CEO \ Bertrand COULOMB
Operations Director \ Pascal LEURAUD

Contact details \ Pépinière Genopole® Enterprises
4, rue Pierre Fontaine - F-91058 Evry Cedex
Tel \ +33 1 60 87 89 80
E-mail \ contact@xentech.eu
Web site \ www.xentech.eu
Date of founding \ April 2006

FIELD OF ACTIVITY

\ XenTech is an innovative biotech company which specializes in the preclinical evaluation of cancer drugs and the identification of prognostic biomarkers.

KEYWORDS

\ Oncology \ Preclinical expertise \ Predictive models \ Biomarkers \ Companion tests.

Background

XenTech has an innovative experimental platform: one of the world's largest collections of solid human tumors xenografted onto immunodeficient mice. The collection is representative of the major types of cancer (breast, lung, colon, prostate, etc.) but also includes rarer tumors (melanoma, ovarian cancer, pancreatic cancer, glioma, soft tissue cancers, etc.).

Description of the products/services/technology

XenTech has an innovative experimental platform: one of the world's largest collections of solid human tumors xenografted onto immunodeficient mice. The collection is representative of the major types of cancer (breast, lung, colon, prostate, etc.) but also includes rarer tumors (melanoma, ovarian cancer, pancreatic cancer, glioma, soft tissue cancers, etc.).

Customer references/collaborations/highlights

XenTech is known worldwide for its expertise in the field of tumor xenografts. The company is developing its expertise in small animal *in vivo* imaging. XenTech is also working up medium-throughput ex vivo screening tests (clonogenicity in agar, spheroid assays, organotypic slices). In France, XenTech works with several companies, including ExonHit, BioAlliance Pharma and PartnerChip.

Collaborations sought

XenTech can provide pharmaceutical companies, biotech firms and academic groups with access to its preclinical expertise and testing facilities on a collaborative research or service provision basis.

→ ANNUAL TURNOVER: €1.2 MILLION → 16 SALARIED STAFF

→ **STRENGTHS:** a unique panel of breast cancers. World-renowned experimental facilities and scientific expertise.